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1. INTRODUCTION  
 
In case of jaundice or bruises the human skin changes in different colors and 
bile pigments become clearly visible. Bile pigments are natural endogenous 
colorful compounds, produced in the catabolism of heme and posses chemical 
structure belonging to the prophyrin family [BULMER, 2008].  
 
Principal substances are bilirubin (yellow) and biliverdin (green). Further 
substances belonging to the group of bile pigments are bilirubin ditaurate 
(yellow/orange), a synthetic, water soluble conjugate and so called 
urobilinogens whereon science is focused to investigate possible positive 
modulatory effects. 
 
In the past, it was thought, that bile pigments were use-less by products of the 
heme catabolism without any protective potential or function. From a medical 
point of view, the only role attributed to bile pigments has been considered as 
potentially toxic compounds, mainly associated with various causes of liver and 
neurological dysfunction, accumulation in the brain (causing kernicterus) or 
hemolytic diseases.  
 
However, during the past 10 years, the interest in this field has been mounting. 
In vivo and in vitro studies, especially focussing on bilirubin, have demonstrated 
that these pigments act as anti-oxidants and possess preventative potential to 
protect the DNA against oxidative damage [www.univie.ac.at/antiox].  
 
While the exact mode of action is hardly known yet, data show that bilirubin 
might reduce the risk of cardiovascular disease and colon cancer. As well, 
protective effects concerning lipids and proteins have been encountered. 
 
Therefore the theory of a beneficial and physiological relevance of bile pigments 
is given.   
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This thesis is a sub-study of a FWF project: “The physiological relevance of bile 
pigments: In vitro to in vivo evidence of antioxidant, antimutagenic, 
anticarcinogenic potential and their mechanisms of action”.  
 
The diploma thesis at hand is especially focused on anti-mutagenic effects of 
specific bile pigments (bilirubin, biliverdin, bilirubin-ditaurate and protoporphyrin) 
and on the theory that the pigments protect against induced mutations, 
examined in the widely known and accepted Salmonella reverse mutation assay 
as a test model.  
 
The aim of this research work was to enhance the understanding of the 
mechanisms and functionality of bile pigments in the human body and to 
communicate physiological effects. 
 
Within this sub-study of the FWF project, so far two diploma theses were done 
in addition to this thesis, written by Andrea Steyrer (stercobilin, urobilin) and 
Gesa Ziesel (bilirubin dimethylester, biliverdin dimethylester).   
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2. LITERATURE SURVEY 
 
In general, bile pigments come from the latin words “bilis” (bile) and “ruber” (red) 
and include following eight different key pigments: bilirubin (BR), biliverdin (BV), 
bilirubin ditaurate (BR-DT), portoporphyrin (PRO), stercobilin (S), urobilin (U), 
bilirubin dimethylester (BR-DME) and biliverdin dimethylester (BV-DME)  
 
2.1. Historical review 
 
Since thousands of years, bile pigments, especially BR plays an important role 
in the traditional Chinese and Indian medicine. Oral supplementation in different 
forms was considered as remedy with beneficial effects to prevent variety of 
disorders [BULMER, 2008]. 
 
Opposite to this, in the western medical practice, the physiological relevance of 
bile pigments were discussed and investigated only since the mid-20th century. 
It was in the 1950´s when fist studies occupied with the role of bile pigments, 
especially focused on the toxic effects of BR in neonates and how to reduce 
increased circulating BR levels to nontoxic levels.  
 
In 2004 Stocker published a review where he summarized that bile pigments 
are able to stabilize vitamin A and beta-carotine during the intestinal uptake 
[BERNHARD et al., 1954]; further on, he reported on protective reactions of BR 
in conjunction with lipid peroxides [BRODERSEN et al., 1969] 
 
During the past two decades, bile pigments have been intensely debated in 
terms of not only being useless toxic by-products of the heme catabolism. 
Although research work is lacking in this area, it is believed, that bile pigments 
possess physiological relevance in the human body.  
 
Nowadays, it is actually presumed that people affected by Gilbert´s syndrome 
possessing a hereditary deficiency in hepatic glucuronosyl transferase activity –  
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which until today was assumed as negative - might have positive effects. It is 
believed that raised “safety factors” against cardiovascular diseases exist in the 
blood in these people, because of persistent enhanced levels of BR. This theory 
is widely believed, but published data is scarce.  
 
Latest published studies confirmed ditto beneficial effects in various fields of 
cancer, cardio- vascular disease and congenital bilirubin- metabolism disorders, 
including several modulatory properties such as anti-complement, anti-
inflammatory and anti-viral effects in vitro [BULMER et al., 2008].   
 
2.2. Principles of physiology 
 
Among the mammals, BR is the principal end product of the heme catabolism. 
The major source of BR are senescent erythrocytes, which are located mainly in 
the spleen and bone marrow. BR accrues in consequence of erythrocytes 
degradation and is referred to as unconjugated BR (UBR) [LÖFFLER; 2005].  
BV, the biogenetic precursor of UBR is also formed during the catabolism of 
heme [SANJEEV and LIGHTNER, 2010]. UBR is released in the physiologic 
blood circulation- tightly bound to albumin – in order to be transported to the 
liver, from where it is removed mainly through uptake by hepatocytes. Less than 
0.1% of the total BR is circulating in an unbound form (free BR); this free BR 
activates the diffusion of UBR into tissues - that´s why free BR is responsible for 
both - its beneficial and its toxic effects on cells [VITEK and OSTROW, 2009].  
 
In the liver, conversion to conjugated BR happens by connecting with glucuronic 
acid and BR becomes more water soluble. Large quantities of CBR are 
produced daily in the human body which correspond roughly to the daily 
amounts of degraded hemoglobin- about 220mg /per day [LÖFFLER, 2005].  
 
Within common blood tests, total BR (TBIL) is assessd which expresses 
parameter of all kinds of BR which appear in the blood.  
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2.2.1. Metabolism of bile pigments  
 
The metabolism of bile pigments proceeds along a series of stations.  
Degradation of heme, mainly located in the spleen, plays a key role in bile 
pigment metabolism. It is a very complex chemical reaction including many 
catalyzing enzymes like hemoglobin, myoglobin, cytochromes and other 
hemoprotein enzymes [BLANCKAERT, 1981].  
Beside the pigments BR and BV, also PROT- hemin´s non-chelated precursor- 
is present in the metabolism and catabolism of heme. Research work is focused 
on PROT, because differences in anti-mutagenicity between PROT and heme 
are expected (based on their chemical structure) [BULMER et al., 2008] 
 
In nature, important cyclic tetrapyrroles related to heme (beside hemoglobin and 
heme containing enzymes) are chlorophylls, and vitamin B12. Chlorophylls 
contain magnesium as the central atom and is derived from protoporphyrin-IX; 
Vitamin B12 is derived from uroporphyrinogen-III. 
In birds and reptiles, the catabolism stops at the step of BV; no conversion to 
BR happens because BVR is lacking [BLANCKAERT, 1981]. Why the 
metabolism and catabolism of heme do not stop at the level of BV in humans? 
Due to the fact that the step of conversion to BR needs energy it is still on open 
question until today and is essential to be investigated in future [SEDLAK and 
SNYDER, 2004].  
 
BV, the first oxidative product of heme decomposition is accomplished via the 
action of cytochrome P450 reductase and heme oxygenase. BV is immediately 
reduced by biliverdin-reductase to unconjugated bilirubin (UCB). UBR arrives- 
albumin bound into the liver, where UBR is transformed via the enzyme uridine 
glucuronosyl transferase to BR mono or diglucuronides. This chemical 
conversion is necessary to metabolize BR in a water-soluble form and to 
facilitate the secretion into the bile duct and the intestine [LÖFFLER, 2005, 
BULMER et al., 2008].  
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Figure 1 Reactions of heme degradation  
Intestinal, bacteria decompose the glucuronic acid and transform BR to 
stercobilins and urobilins. Without this step, BR would accumulate to toxic 
levels.  
As well, small proportions of the intermediate products are reabsorbed into the 
liver via enterohepatic circulation.  
 
Residues reach the kidneys and get eliminated in the urine. The major part of 
stercobilin gets excreted with the faeces which is therefore responsible for the 
pigmentation of mammalian faeces [LÖFFLER, 2005].  
In adults, the daily production of BR is about 250-350 mg; its excretion in the 
faeces is estimated to about 220 mg per day [BLANCKAERT, 1981].  
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Figure 2 Steps of hemoglobin metabolism [ http://usmle-review.com/]  
 
To clarifying why BV is converted in the poorer soluble BR, science is focused. 
BR and its hydrophobic properties contain a range of disadvantages like 
neurotoxicity or propensity of gall stone but principally, a further metabolizing 
procedure is needed. Obviously, these disadvantages were compensated by 
the lipophilic antioxidative properties of BR [LÖFFLER, 2005].  
 
2.2.2. Pathopysiolgogy 
 
Non pathologic plasma concentrations of BR amount to 17 µmol/l. 
Hyperbilirubinemia is spoken of when plasma concentrations exceeded this  
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value. Concentrations at or above 30 µmol/l BR becomes visible in the skin 
[SILBERNAGEL, 2005].  
 
Classifications of hyperbilirubinemia are very complex and may depend on 
various causes and conditions: 
- Prehepatic icterus (enhanced BR production, for example appears in 
case of haemolysis, ineffective erythropoiese or blood loss) 
- Intrahepatic icterus may become manifest in 3 different forms: 
- defected absorption of BR into hepatocytes (Gilbert –syndrome)  
- defected conjugation process in the liver (Crigler-Nijjar-syndrome, 
Gilbert-syndrome, Newborn icterus)  
- posthepatic icterus effects extrahepatic bile ducts, which can be caused 
by tumors, gall stones or pancreatitis [BESTE, 2003] 
 
Different syndromes like the Gilbert -syndrome, Crigler-Najjar-syndrome, Dubin-
Johnson syndrome, Rotor syndrome are part of the so called inherent 
hyperbilirubinemia, while the haemolytic, hepatocellular and newborn icterus 
belong to the acquired hyperbilirubinemia.  
Further classification is possible according to the differentiation of BR 
concentrations of conjugated and unconjugated BR. Excessive levels of indirect 
BR is called unconjugated hyperbilirubinemia (for instance Gilbert -syndrome, 
haemolysis or in case of sepsis); dysfunction of secretion is called conjugated 
hyperbilirubinemia as it is the case with gall stones, occlusion or tumors for 
examples [BESTE, 2003].  
 
General symptoms of all these diseases are the accumulation of BR which is 
reflected in jaundice or icterus. Therefore BR is generally regarded as 
potentially cytotoxic - that´s why BR needs to be excreted [BESTE 2003]. 
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2.3. Chemistry of bile pigments 
 
2.3.1. Structural aspects 
 
Bile pigments share a few characteristics including porphyrin structure or linear 
tetrapyrrolic construction and possess two free or conjugated propionate 
groups. These groups are responsible for binding molecules which improve 
solubility excretion and transport around the body [BULMER, 2008].  
 
 
 
Figure 3 Two and three-dimensional structures of bilirubin (1), biliverdin (2) and bilirubin-
ditaurate (3) [BULMER et al., 2008] 
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As depicted, BR and BV possess different molecular geometry. The most stable 
form of BV is the helical lockwasher shape; BR has a folded ridge tile 
conformation [GONCHAROVA and URBANVOVÁ, 2008].  
 
Detailed information on the structural aspects of these compounds became 
available only with the advent of modern spectroscopic methods. Rich palettes 
of spectroscopic tools have been developed and have been used to solve 
constitution problems [FALK, 1989].  
 
UBR as the principal degradation product of heme is the particular isomer in the 
human body. Generally, the chemical structure of bile pigments is very complex: 
naturally occurring pigments are formely known as BR IXalpha (Z,Z) and BV IX 
alpha (Z,Z). This isomer specification represents the different locations and 
forms of the side chains of the whole molecule [BLANCKAERT, 1981].  
 
Nowadays these additional signs are omitted and chemical structures are 
simply called BR and BV. In older literature, many of such additional 
designations may still be used.  
 
2.3.2. Solubility of bile pigments 
 
For biological assays, it is truly essential to bring bile pigments into solution.  
Depending on pigments to be solved, complete solution is often a hard 
challenge and needs very special handling.  
 
BR in all variations is a linear, lipophilic compound with water-insoluble 
properties at physiological pH (less than 1nM at pH=7 and about 0.1 µM at 
pH=8) [BLANCKAERT, 1981].  
 
Due to the presence of two propionate groups one might expect that BR would 
dissolve in water- but in reality it is different! [BULMER, 2008].  
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Although the three-dimensional structures of BR and BV are very similar (see 
figure 3), their solution conformations differ greatly [GONCHAROVA and 
URBANOVÁ, 2007].  
 
Methanol and other polar solvents are incapable of forming hydrogen bonds 
with BR, so there is no way to bring BR into solution with polar solvents. 
Nevertheless, UBR dissolves in chloroform, dimethyl formamide, alkali 
solutions, dimethly sulfoxide (DMSO) and in most lipid solvents [BRODERSEN, 
1979].  
 
In the Salmonella mutagenicity assay, the most effective and common way to 
solubilize bile pigments is the use of dimethly sulfoxide (DMSO) [BULMER et 
al., 2007] - a hydrogen bond-breaking solvent [OSTROW and CELIC, 2008]. 
The estimated solubility limit of bile pigments in DMSO amounts to 0.034 M, the 
maximum within the assays was about 3.42 µmol/plate (in 100 µL) [BULMER et 
al., 2008].  
 
Pilot studies have been accomplished to investigate the maximum of a non toxic 
dose of DMSO without precipitation when PBS or S9 were added. The outcome 
of these solubility experiments was, that the dose of bile pigments could be 
maximized to 2 µmol/plate for BV, BRT and PROT and 0.75 µmol/plate for BR 
[BULMER et al., 2008].  
 
In contrast to BR, BV is polar and more soluble. Both, BR and BV form non- 
covalent albumin complexes within the blood circulation (with optical activity) in 
order to increase the solubility of these compounds. This step in metabolism 
plays a crucial role in neutralizing the toxicity of BR [GONCHAROVA and 
URBANOVÁ, 2008]. 
 
 
 
12 
 
In contrast to BR and BV, BRDT is a synthetic commercially available 
compound which has been used as a surrogate for bilirubin diglucoronide and in 
animal studies [GONCHAROVA and URBANOVÁ, 2007].  
 
2.4. Antioxidative activities of bile pigments 
 
In the past, bile pigments were generally regarded as harmful by-products of 
heme catabolism without any beneficial function. Damaging effects of BR and 
BV have been associated with jaundice, especially in newborns or hepatic 
insufficiency and were considered as toxic compounds [BULMER et al., 2008]. 
Plasma concentrations of >300 µM have been associated with accumulation as 
a consequence thereof with the risk of toxic effects in cell functions [STOCKER, 
2004]. 
 
Scientific research for the antioxidant activity of BR and BV was started in the 
mid 19 th century. It was already in the early 1950 when for the first time BR 
was reported to prevent oxidation of lipids (e.g. linoleic acid), vitamin A and ß-
carotene during intestinal uptake [SEDLAK and SNYDER, 2004; STOCKER, 
2004].  
Although these data were published already in the 1950, it was only in the late 
1980 when Ames and co-workers established further research findings, that 
BR´s antioxidative capacity toward lipid peroxidation overtopped that of vitamin 
E [BURTON and INGOLD, 1986]. 
 
In fact, since the last two decades there is a continuing interest by scientists in 
the research field of bile pigments to investigate the beneficial effects as 
physiological antioxidants which have been reported by various groups [VITEK, 
2005; HATFIELD and BARCLAY, 2004]. As well, it is suggested that BR 
possesses multiple biological activities [LIU et al., 2008]  
As mentioned above, BR possesses beneficial and damaging effects in 
biological systems [HATFIELD and BARCLAY, 2004]. The concentration, 
localization as well as binding and blood circulation of BR are crucial to achieve  
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the balance between deleterious cytotoxic and beneficial anti-oxidative effects 
[TOMARO et al., 2002].  
This chapter is focused on the positive and preventative properties of these 
compounds. 
 
2.4.1. General aspects of antioxidants 
 
Human health is protected and controlled by an antioxidant defense system. 
Therefore endogenous enzymes like GSH, SOD, catalase, glutathione 
peroxidase, are essential for maintaining health in the human body. Under non 
pathological conditions, this protection system is at least in balance between 
pro-oxidants (e.g. light, radiation, metalloions, chemical substances) and 
antioxidants, favouring for the latter. This “network” protects living organisms 
from tissue injury and the deleterious process of radicals [THEILER, 2009]. 
 
An imbalance in favor of oxidants leads to oxidative stress and consequently to 
high levels of reactive oxygen species (ROS) and nitrogen species (RNS) 
[VERTUANI et al., 2004]. Both species, ROS and RNS, evolutionary developed 
as natural waste products in the metabolism, possess deleterious function in the 
body and work as cell signaling and mediator molecules (damaging cell 
structures, lipids, membranes, proteins and DNA) in the living organism [VALKO 
et al., 2007].  
 
To achieve the balance between the deleterious and beneficial face of these 
radicals, the human body requires a number of proteinous (endogenous 
enzymes) and nonproteinous antioxidants (micronutrients absorbed via food).  
 
Endogenous antioxidants like specific enzymes, bilirubin, uric acid, glutathione 
or ubiquinon and exogenous (non enzymatic) antioxidants such as tocopherols, 
caritinoids or ascorbic acid possess a central role and generally act together in 
cellular defense [THEILER, 2009]. 
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Together, an overproduction of ROS results in oxidative damage which is an 
important factor in numerous pathological conditions and occupies a central role 
in a variety of diseases like cancer, atherosclerosis, rheumatoid arthritis, viral 
infections [NEUZIL et al., 1993] cardiovascular diseases or diabetes, as well as 
in infections, inflammations [SEDLAK and SNYDER, 2004] and in the ageing 
process [VALKO et al., 2007]. 
 
2.4.2. Antioxidative capacities of bile pigments in literature 
 
To interact as antioxidants, the chemical structure of bile pigments is a decisive 
factor. BR in its different forms (free, albumin-bound and conjugated) has 
conjugated double bonds and a pair of reactive hydrogen atoms which are 
responsible for the H-donation, the main pathway for its antioxidative activity. 
In contrast, BV´s chemical structure only exhibits conjugated double bonds, so 
that the antioxidative capacity of BV is due to the formation of a resonance-
stabilized, carbon centered radical [STOCKER, 2004].  
 
2.4.2.1. Modulatory effects towards oxidation of lipids and 
proteins  
 
As mentioned above, Stocker and Co-workers (1987) were the first to publish a 
series of in vitro studies on the behavior and physiological reactions of bile 
pigments as a protective agent with possible antioxidant potential in living 
organisms. 
 
It was in 1987 when the idea of a ´beneficial´ role of BR arose with the 
suggestion that BR suppressed lipid peroxidation to a greater extent than alpha 
tocopherol [STOCKER et al., 1987].  
 
An antioxidant-protective function of BR was also confirmed by Neuzil and 
Stocker (1993). In general, when BR interacts as an antioxidant, it is itself 
oxidized to BV and then rapidly reduced back to BR via BVR, an abundant  
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enzyme with a high turnover rate [SEDLAK et al., 2008; SEDLAK and SYNDER, 
2004; BARANANO et al., 2002].  
 
The published review form Stocker (2004) described a chemically defined and 
controlled thermolabile test model system to examine bile pigments, focussing 
on BR, UBR, CBR and BV. Published data came to the result, that all forms of 
BR were effective against peroxyl radicals in homogeneous solutions or 
multilamellar liposomes.  
Under these conditions, the antioxidative potential of BR in liposomes actually 
exceeded that of alpha tocopherol, the most active form of vitamin E, which is 
generally regarded as the best known protective agent concerning lipids and 
proteins [NEUZIL et al., 1993]. Under these conditions, BV, compared with all 
forms of BR, was still more effective in scavenging radicals [STOCKER, 2004].  
 
A study of Ritter (2002) also confirms that nanomolar amounts of BR were 
sufficiently working against peroxyl radicals. 
 
Besides the above mentioned effects, BR and BV were also described as 
synergists with membrane-bound alpha tocopherol, demonstrated within the 
liposome membranes in the presence and absence of membrane bound alpha 
tocopherol.  
Summarizing, it can be concluded that in absence of alpha tocopherol, the lipid 
peroxidation proceeded linearly; micormolar amounts of CBR or BV inhibited 
this oxidation and the induction period increased substantially in the presence of 
alpha tocopherol and one of the two bile pigments. The same results the 
prevention of lipid peroxidation were shown with CBR and UBR [STOCKER, 
2004].  
 
In another experiment, Hatfield and Barclay (2004) focused on the antioxidative 
potential and activity of BR reactions in 3 different media. The antioxidative 
capacity of BR was mainly depend on the used medium. A weak antioxidant  
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activity was shown in nonpolar solution (styrene or cumene in chlororbenzene); 
strong effects were demonstrated in aqueous lipid bilayers or in micelles of SDS 
(in polar solutions).  
 
It has also been reported that BR and BV were able to scavenge various other 
RONS. It is highly probable, that BR and BV were effective against both, 1e-and 
2e- oxidants, similar to ascorbate. This behavior is a special feature of BR and 
BV, because other antioxidants are exclusively effective against one class of 
oxidants [STOCKER, 2004].  
As mentioned above, BR and BV are effective reducing agents and possess 
antioxidant activity in various in vitro systems. In in vivo studies, the 
antioxidative role of these pigments is less clear and less proven. Up to date, 
there exists only indirect evidence in such in vivo situations, like the role of HO-
1 and its impact on the cellular heme and iron status.  
 
Although, most findings are not entirely evident, the antioxidative activity of BR 
and BV is believed in situations of raised oxidative stress or low protection 
system.  
 
To improve further research work, it might be useful to investigate the effect of 
altered pigment concentrations on established in vivo markers e.g. oxidized 
lipids [STOCKER, 2004]. For instance, Dennery et al. (1995) documented a 
decrease of oxidative damage makers (thiobarbitureic acid and lipid 
hydroperoxides) after exposure to oxygen, in hyperbilirubinemic gun rats 
compared with nonjaundiced littermates. The study yielded showed an in vivo 
antioxidant activity of BR, but for future studies more direct testing would be 
necessary to confirm these first results.  
 
2.4.2.2. Antioxidative effects of albumin-bound bilirubin 
 
Stocker et al. (1987) published data whereupon BR protects fatty acids 
transported on albumin from oxidative damage. Further on, albumin-bound BR  
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was a 30 times more effective radical scavenger than unbound BR was 
[STOCKER 2004].  
 
But albumin-bound BR (up 15 µM) is not the major radical scavenger in the 
extracellular space; main competitors are ascorbate (less or equal 50 µM) and 
urate (less or equal 300 µM). However, more important than the quantitative 
character are qualitative considerations, for instance which antioxidant is first 
depleted and limited in case of increased oxidant production [STOCKER, 2004].  
 
In the nineties, studies of Frei et al. (1988) investigated the time dependent 
consumption of antioxidants in conjunction with the accumulation of lipid 
hydroperoxides and came to the result that albumin-bound BR represents a 
second line antioxidant defense against peroxyl radical-induced lipid 
peroxidation in extracellular matrix and further, that albumin-bound BR inhibits 
lipoprotein lipid peroxidation in absence of ascorbate and urate. 
 
Besides, a range of studies display that albumin-bound BR protects proteins 
against oxidative damage by different types of RONS [KAPITULNIK, 2004].  
 
Neuzil et al. (1993) confirms also that BR act as protector of albumin-bound 
fatty acids against peroxyl-radical-mediated oxidation in vitro; further on, when 
BR was absorbed in liposomes, they suggested that BR acted as an agent with 
possible chain-breaking antioxidant activity as effective as alpha tocopherol 
[STOCKER et al., 1987]. 
 
In summary binding of BR to albumin increased specificity and reactivity against 
various RONS and increased also protection of lipids and protein [STOCKER, 
2004].  
 
2.4.2.3. The theory of a possible redox-cycle of bilirubin and 
biliverdin 
 
As mentioned above, for several years, BR and BV have been considered as 
strong antioxidants. While the basic mechanism how BR can protect cells 
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against oxidative damage is currently unknown, it is believed that the 
antioxidative function of BR arises from a redox cycle in which BR is oxidized to 
BV and then recycled back by the ubiquitous BVR [MAGHZAL et al., 2009].  
 
The theory of such mechanism are based on studies, which assessed the heme 
oxygenase system [SEDLAK and SYNDER, 2004].  
 
Test procedures of cell membrane-bound BR (carried out with chloroform and 
hydrogen peroxide) found that both substances did not generally oxidize 
albumin-bound BR to BV and BVR is not an important cellular protector. 
Nonetheless, it is possible that BVR possess an antiapoptotic activity, but 
further studies in this field are necessary in future [MAGHZAL et al., 2009]. 
Whereas Baranano et al. (2002) published a study, whereupon data proposed 
that this redox cycle may represent the cytoprotective role of BVR cycle as the 
principal physiological function of BR.  
 
These findings are not clear in assuming the theory that the BVR mediated 
redox cycle plays an important role in cellular defense and demonstrate, that 
scientific research in this field is still at the very beginning [MAGHZAL et al., 
2009].  
 
2.4.2.4. The role of heme and heme oxigenase 
 
In vertebrates, the most abundant source of heme is haemoglobin. The 
potential toxicity of heme is a critical factor concerning heme degradation in the 
cellular metabolism. Through enzymatic conversion of the HO system, (HO 
exists in three isoforms) bile pigments are formed in the blood.  
 
HO-1 (regarded as one of the heat shock proteins) is described as “remarkable 
inducible enzyme” and occurs ubiquitary in many tissues; the most substantial 
source is the spleen, where it is activated by heme from senescent red blood 
cells [SEDLAK et al., 2008; SEDLAK and SYNDER, 2004].  
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HO-2 and HO-3 are considered as “constitutive enzymes” [STOCKER, 2004] -
synthesis is arranged by neuronal activity- and are mainly located in the brain 
and testes. In the peripheral nervous system, the heme ring of HO is cleaved 
and CO is produced (which seem to possess a neutrotransmitter function). Due 
to this fact, BV is formed, which is immediately reduced back to BR by BVR 
[SEDLAK et al., 2008; SEDLAK and SYNDER, 2004]. The reason, why the 
more water soluble and therefore more readily excreted BV is metabolized back 
to BR remains unclear until today [SEDLAK et al., 2008], because it is an 
energetically expensive, potentially toxic and apparently unnecessary step in 
mammal metabolism. One possible approach would be, that BR is placenta 
crossing and therefore a convey from fetal to maternal circulation can happen 
more easily [BARANANO et al., 2002].  
 
Generally, catabolic heme pathways including HO activity produce both, pro- 
and antioxidant compounds which might have effects on the cellular redox 
potential [TOMARO et al., 2002].  
 
Induction of HO-1 is a defense reaction in cells in case of oxidative stress. For 
instance, it is implied that, HO-1 induction works against lipid-peroxidation and 
vasospasm [MATZ et al., 1996].  
One main result of gained HO-1 activity is increased bile pigment 
concentrations in the body. BR and BV possess antioxidative properties and 
represent the adaptive response of cells to oxidative stress [TOMARO et al., 
2002].  
 
Tomaro et al. (2002) investigated the field of HO and evidenced that BR was an 
effective marker against oxidative damage in the liver of rats. Treated with 
various chemicals, it became apparent that ROS rapidly decreased reduced 
glutathione levels and after that, they induced HO activity.  
This HO induction triggered an increase of ROS and a decrease of the anti-
oxidant defense system. By having used BR before the treatment with an 
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oxidative stress inducer was started, it was clearly evident that BR prevented 
HO induction, GSH decrease and ROS increase in all assays.  
In conclusion, collected data of the study imply that UBR is a chain breaking 
anti-oxidant and scavenger of various peroxide radicals.  
 
Together, BR plays a key role in cellular protection and works efficiently against 
oxidative damage [TOMARO et al., 2002].  
 
2.4.2.5. Complementary antioxidative and cytoprotective role of 
bilirubin 
 
2.4.2.5.1. Cytoprotective effects of bilirubin and 
gluthatione  
 
It was long believed that glutathione (GSH), a tri-peptide and well established 
cellular antioxidant, formed by glutamic acid, cysteine and glycine, was the most 
important cellular antioxidant to protect cells from oxidative damage, because of 
its high concentration in tissues (millimolar) [SEDLAK et al., 2004].  
 
Although glutathione was considered as the most important and prominent 
cellular antioxidant during the last 80 years [RITTER, 2002] today, it is arguable, 
that BR provides increased cytoprotective effects in vitro, although BR levels in 
tissues were 10.000 times lower than GSH. 10 nm BR protected cells against 
10.000 fold higher concentrations of hydrogen peroxide [SEDLAK et al., 2004; 
MAGHZAL et al., 2009].  
 
Besides the above mentioned differences in tissue concentrations, also the 
enzymatic regulation differentiates in these two systems. GSH recycling 
requires peroxidase and reductase activity for synthesizing the antioxidant; BV 
is directly oxidized to BR without the need of other enzymes [BARANANO et al., 
2002].  
 
Although remarkable differences can be found in tissue concentration and 
enzymatic regulation, several parallels can also be demonstrated. For instance, 
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both substances imply an oxidized and a reduced form (the latter particularly 
arises under healthy conditions) [BARANANO et al., 2002].  
 
Why do cells evolve two different antioxidant defend systems?  
Due to the fact, that BR (highly lipophilic) was found in the blood at high 
concentration, it is conceivable, that BR is the major protector for cell 
membranes against lipid peroxidation, while GSH (highly hydrophilic) interacts 
protectively with water soluble proteins inside cells. A possible overlapping 
function of both antioxidant defense systems is subject of debate [SEDLAK et 
al., 2004; SEDLAK et al., 2008].  
 
Besides the above mentioned effects of BR and GSH, it appears that cells use 
multiple “antioxidant network” to defend human health against oxidative stress 
and ROS, e.g. free heavy metals are regulated by chelators (such as ferritin and 
transferrin), together SOD and catalase convert superoxide to water or 
ascorbate and vitamin E act as direct antioxidants by catching free radicals 
[SEDLAK and SYNDER, 2004; BARANANO et al., 2002]. 
 
2.4.2.5.2. Further modulatory effects of bile pigments 
 
The beneficial and physiological actions of bile pigments as an endogenous 
tissue protector was also examined by Nakagami et al. in 1993. Published data 
show that bile pigments possess anti-complement properties and therefore 
could be involved in tissue protection. Examinations showed inhibitory effects of 
BV in complement cascade reactions in vitro and also in associated 
complement reactions in guinea pigs; UBR showed complement-dependent 
reactions in vitro. So this study represents another example for a protective role 
of bile pigments in tissue protection [NAKAGAMI et al., 1993].  
 
Immunological importance of bile pigments was confirmed and published by Liu 
et al. (2008). The results clearly showed significantly powerful suppressing 
effects on both, polyclonal and Ag-sepcific T cell responses, while other known 
antioxidants did not exhibit these effects. Liu et al. identified BR as a potent 
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immunomodulator that might protect mammals against immune disorders 
(multiple sclerosis and other autoimmune diseases).  
 
Furthermore, it is believed that, bile pigments may have an important biological 
function in other fields to maintain human health. For instance, it is discussed 
that BR plays an evolutionary role in the REM sleep and also has a large share 
on the light´s anti-depressant effects [OREN et al., 1997].  
Besides the above mentioned capacities of bile pigments, several other 
modulatory effects of bile pigments were discussed in literature, e.g. anti-viral, 
anti-apoptotic and anti-mutagenic effects (see next chapter) [BLUMER et al., 
2008]. 
 
2.5. Antimutagenic properties of bile pigments in the Salmonella Ames 
Test 
 
Within this sub-study, the widely accepted and popular Salmonella mutagenicity 
assay was used as test model to detect potential anti-mutagenic effects of BR, 
BV, BRDT and PROT.  
 
2.5.1. The Salmonella Ames Test 
 
The Ames Test is a short-term bacterial reverse mutation assay designed to 
detect a wide range of chemical substances that can produce genetic damage 
that leads to gene mutations [MORTELMANS et al., 2000]. 
 
To describe and report substances, capable of inducing mutations or cancer, 
the Ames Test is used world-wide as an initial screening method to elicit 
mutagenic potential of chemicals and drugs [MORTELMANS et al., 2000]. 
 
Over the years, the Ames Test has been securely established and developed, 
so that today uniformity of testing procedures can be ensured Therefore, within 
scientific communities and corporations, the Ames Test is a commonly used 
method and pays a key role in safety assessment [MORTELMANS et al., 2000]. 
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2.5.1.1. Historical background 
 
The Ames test has been developed in 1964 when Bruce Ames found different 
mutants of Salmonella typhimurium bacteria, unable to form the amino acid 
histidine and therefore, unable to form colonies. Due to the fact, that bacteria 
reverted to their wild form after adding mutagenic substances, this test is often 
referred to as “reversion assay”. 
 
Over the years, mutants were selected which were sensitive to reversion by a 
variety of chemicals mutagens. Within test procedures, various tester strains 
were used to differentiate types of mutations in the histidine operon like base-
pair mutants and frameshift mutants [MORTELMANS et al., 2000]. 
In 1973, Ames et al. improved the spot test procedure of 1966 (mutagen 
screening with an E.coli strain) and created the so called incorporation assay 
procedure. Over the years different groups developed this incorporation assay 
to improve the sensitivity of the test so that nowadays it is possible to test a 
wide range of chemicals, gases and volatile substances [MORTELMANS et al., 
2000]. 
 
2.5.1.2. Metabolic activation systems 
 
In mammalian, several carcinogenic chemicals are biologically active until they 
are metabolised to inactive forms or vice versa via the P450 metabolic 
oxidations system, which is mainly located in the liver. Due to the fact, that 
bacteria do not have a similar metabolic oxidation system like the cytochrome-
based P450 system, an exogenous metabolic activation system needs to be 
added within the test procedure.  
 
In fact, it was the key to success that Ames et al. (1973) included this S9 
fraction in the test procedure. Consequently, the test procedure became highly 
sensitive, more quantitative and meaningful for science. This activation system 
is called S9 microsomal fraction and is a mix of oxidase enzymes obtained from 
animals (liver homogenate), treated with Acrolor 1254. For chemicals, which 
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include azo and diazo bonds, the metabolic activation system also contains 
reductive enzymes.  
 
In mammalian, metabolism and reduction of chemical substances a part takes 
in the intestional wall place via the anaerobic intestinal microflora or in the liver. 
In in vitro studies, this reductive metabolism is generated based on liver 
homogenate supplemented with FMN (Flavin mononucleotide) and as well 
based on rat intestinal microflora preparations (see chapter “Materials and 
Methods”) [MORTELMANS et al., 2000]. 
 
2.5.1.3. Salmonella tester strains  
 
A set of standard tester stains were used within mutagenicity testing of 
chemicals to detect different types of mutations in the histidine operon. 
Additional other mutations/genetic alterations have been inserted in the 
standard tester strains to make these strains more sensible to detect mutagenic 
substances in the test procedure (e.g. uvrB-mutation, rfa mutation or pKM101). 
 
Within this sub-study, tester strains TA 98 and TA 102 were used: 
Mutation Bio chid uvrB gal LSP defect Plasmid 
TA 98 
his D3052 
Deletion mutation rfa 
pKM101 
(ampicilin 
restistence) 
    
TA 102 
his G428 
Wild type rfa 
pKM101, PAQI 
(tetracycline 
resistance) 
Table 1 Genotype of the exerted Salmonella tester strains [MÖLZER, 2007] 
 
TA 98 and TA 102 contain a rfa mutation that leads to a damaged 
lipopolysaccharide (LPS) layer (rfa mutation affects the permeability of the cell 
wall) and increase permeability in the bacteria to large chemicals which do not 
permeate under normal conditions.  
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TA 98 has a his D3052 frameshift mutation which affects the DNA sequence –
C-G-C-G-C-G-C-G-.  
In contrast, TA 102 has an AT base pair at the his G428 mutant site and 
belongs to the set which are susceptible to oxidative compounds [MÖLZER, 
2007].  
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2.5.1.4. Commonly used mutagens within the Ames Test 
 
Commonly used mutagens within the Ames Test can be divided in three classes 
[BULMER et al., 2008]: 
 
- Mutagens, derived from processes involving combustion: e.g. 
benzo[alpha]pyrene- which is polycyclic aromatic hydrocarbon derived 
from fossils fuels and commonly used in the Salmonella mutagenicity 
assay (B[a]P); nitroarenes derived from combustion of diesel fuel; 4-
nitropunoline-1-oxide (4NQO) which accrues form the combustion of 
tabacco; these mutagens are mainly present in the atmosphere and 
therefore contribute to the development of cancer, particularly of the 
respiratory tract.  
- Mutagens, found in food products, formed as a consequence of 
processing or cooking. It is thought that its metabolism can result in 
genotoxicity; e.g. amino acid pyrolysate products of tryptophan, glutamic 
acid or soy beans, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP), aflatoxin B₁ (AFB₁) 
- Miscellaneous mutagens: e.g. 2-4-7 trinitrofluenone (TNFone), a 
nonplanar, polycyclic nitro-amine which is found in photocopy toner, 2-
aminofluorene which is a planar heterocyclic amine and synthetically 
produced; tertiary butyl hydroperoxide (t-BOOH) which is an organic 
hydroperoxide and oxidant. 
 
Within this sub-study aflatoxin B₁ (AFB₁) and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) were used as representatives for 
mutagens, since they are particularly found in food products [BULMER et al., 
2008]. 
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2-4-7 trinitrofluenon (TNFone) and tertiary butyl hydroperoxide (t-BuOOH) were 
included in test procedure representing pro-oxidants for TA 102 and are 
commonly not found in environment.  
 
2.5.2. Antimutagenic effects of bile pigments in the Salmonella Ames Test 
 
Bulmer et al. published the first review on anti-mutagenic effects of bile 
pigments in 2008. They summarised 12 studies describing antimutagenic 
properties of bile pigments, within cultured bacterial studies.  
Most of these studies dealing with the antimutagenic effects of porphyrins were 
realized in the period from 1980 to 2000.  
 
2.5.2.1. Literature survey of studies of mutagens, derived from 
processes involving combustion 
 
Arimoto et al. (1980) investigated different kinds of porphyrins (hemin, BR, BV) 
and confirmed that these compounds inhibited induced mutagenicity by B[a]P in 
tester strain TA 98. The results showed a potent antimutagenic effect of all 
tested substances. Within the bile pigments, BR showed a greater effect than 
BV. 
 
Hemin, a chelated porphyrin, seemed to be more effective than bile pigments 
and could inhibit the mutagenic response of B[a]P - it is believed, that hemin 
can chemically bind B[a]P [ARIMOTO et al., 1980].  However, in a recently 
published study by Blumer et al. (2007) BR and BV showed complete conflictive 
results in effectiveness. 
 
In a later study of Arimoto et al. (1995) once again an anti-mutagenic effect of 
BR and BV was confirmed in tester strain TA 100, this time in presence of 
metabolic activation. Further weak antimutagenic effects were shown against 
B[a]P metabolites B[a]P-4,5-epoxide and B[a]P-7,8-diol-9,10-epoxide.  
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Further metabolites of B[a]P (Sulfoxymethylbenzo[a]pyrene (SMBP) and 6-
hydroxymethylbeno[a]pyrene (HMBP)) were tested by Cho et al. (2000) in the 
bacterial strain TA 98. Mutagenesis by the above mentioned mutagens was 
tested with selected porphyrins: BV, PROT, hemin, chlorophyllin and 
phtalocyanines. The results showed that the porphyrins were more effective 
against SMBP compared to HMBP. More precisely, BV and hemin were 
absolutely ineffective against HMBP.  
Studies concerning antimutagenicity testing of mutagens and metabolites of 
tobacco compounds were done by Romert et al. in 1994 and in 1992. In 1992 
no antimutagenic effects were displayed referring to tobacco specific 
nitrosamine and BV. This result was critically discussed, since it can be 
distorted as a consequence of too low doses of BV and mutagen.  
 
In a further study by Romert et al. in 1994 porphyrins, including BV were 
investigated in the bacterial strains TA 98 and TA 100 in the presence of 
metabolic activation. The applied mutagen was cigarette smoke condensate 
(CSC). Due to the fact, that BV showed greater antimutagenic effects in TA 100 
than in TA 98 it is believed, that BV is able to prevent base-pair mutations. In 
1994 Camoirano et al. also confirmed antimutagenic effects of BR in TA 98 and 
TA 100 with the same mutagenic condensate of CS.  
 
Concerning 4NQO, studies were done by De Flora et al. (1994) and Camoirano 
et al. (1994). Camoriano tested BR´s response with 4NQO in TA 98 and TA 100 
and found an antimutagenic effect. Besides BR, BV was also tested in this 
study in TA 100 but no protective effect was shown in this set of experiments.  
 
De Flora et al. (1994) confirmed the above mentioned results of Camoirano et 
al. Antimutagenic effects of BR against genotoxicity of 4NQO in TA 100 were 
shown. In 1994 De Flora et al. investigated the possible antimutgenic potential 
of BR more precisely and tested the spontaneous mutations in TA 102 and TA 
104, as a marker for deficient DNA recombination, repair processes and 
production of free radicals that modify genomic structure. Many compounds 
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were tested within this study; BR was only tested in TA 104 and interestingly, no 
effect in spontaneous mutation was shown in this experiment.   
 
2.5.2.2. Literature survey of studies of mutagens, found in food 
products 
 
Humans are regularly exposed to food toxins, formed during the cooking 
process. Typical food mutagens are particularly arcylamide, hetereocylic 
amines, nitrosamines or polyaromatic hydrocarbons. Exposure can increase the 
risk of human cancer [JAGERSTAD and SKOG, 2005].  
 
Arimoto et al. (1980) used pyrolysate products of tryptophan, glutamic acid and 
soy bean to investigate potential antimutagenic effects of bile pigments. In 
presence of S9 and TA 98, BV showed the most pronounced antimutagenic 
effect, but concurrently BV was less effective than hemin, chlorophyllin and 
PROT (under certain conditions).  
 
The reason behind BR´s non antimutagenic effects in this study is presumed to 
be due to a different chemical structure of BR (hydrogen bonded and folded 
conformation) compared to the planar tetrapyrrolic structure of PRO and BV. 
This is a possible theory and may be essential for the antimutagenic binding of 
the amino acid pyrolysis products.  
 
In 1989, Arimoto and Hayatsu continued their investigations of amino acid 
pyrolysis products. The same porphyrins were tested in TA 98 including 
metabolic activation. Again, antimutagenic effects were confirmed, whereby the 
planar molecules of PROT, BV and chlorophyllin were more effective than BR.  
 
Tang and Edenharder (1997) investigated possible antimutagenic effects of 
hemin, chlorophyllin, chlorophyll, BV and BR in TA 98 without metabolic 
activation in the presence of nitroarenes: 2-nitrofluorene (2-NF), 3-
nitrofluoranthene (3-NFA) and 1-nitropyrene (1-NP). The results showed 
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stronger antimutagenic effects of BR and BV than hemin and chlorophyllin. The 
results showed that BR was more effective than BV.  
 
Due to the fact that bile pigments possess antimutagenic activities (see above 
mentioned studies) and the fact that they are present in the bile and intestine of 
humans in high concentrations, it is possible that they can influence the 
genotoxicity of food toxins in human diet [BULMER et al., 2008].  
 
2.5.2.3. Literature survey of studies of miscellaneous mutagens 
 
Examples for such mutagens are 2,4,7 trinitrofluenone (TNFone), 2-
aminofluorene (2-AF) or tertiary butyl hydroperoxide (t-BOOH).  
 
Bulmer et al. (2007) published data on the antimutgenic effects of BR, BV and 
BRDT in the bacterial strains TA 98, TA 100 and TA 102 tested with TNFone, 2-
AF and t-BOOH. It became apparent that antimutagenic effects of the bile 
pigments were dependent on the tested mutagen but independent from the 
bacterial strains which were used.  
 
In this study BR and BV were the most effective compounds against TNFone 
and 2-AF. Related to t-BOOH, results showed that BR was more effective than 
BV. However, BRDT showed no effect referred to t-BOOH.  
 
Due to this study-outcome, the theory has been discussed that antimutagenic 
effects of BR and BV stem from the ability that they donate electrons (BR 
donates 2 electrons, BV donates one electron). Why BRDT showed no 
antioxidative effect remains unclear. It is suggested, that this behaviour of 
BRDT is attributed to structural differences between BR and BRDT or to the 
inability of BRDT to cross lipid membranes.  
 
Summing the data up, the study of Bulmer et al. (2007) was the first that 
confirmed a preventative role of endogenous bile pigments related to oxidative 
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stress induced mutation in TA 102. Therefore it is suggested that bile pigments 
possess possible physiological importance in biological systems.  
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3. MATERIALS and METHODS 
 
3.1. Basic principles of the Ames Test 
 
The so called Salmonella microsome mutagenicity assay is a popular and 
widely accepted test method to detect chemical substances that possess 
mutagenic properties. Over the years, the Ames Test has been steadily 
developed by different research groups to enhance particularly the sensitivity of 
test procedure [MORTELMANS, 2000].  
Within the test, various Salmonella test strains are used with typical known 
foregoing mutations in different genes in the histidine operon. Due to these 
certain types of mutations, bacteria cannot produce the amino acid histidine, 
which is a growth factor to form colonies. A second mutation can reconstruct the 
gene´s function and allow the cells to synthesize histidine and to form colonies. 
These colonies can grow in absence of histidine and will be counted after 
incubation.  
 
To identify substances, capable of inducing mutations, the Ames test is used 
world- wide as an initial screen. Developed international guidelines guarantee 
the uniformity of test procedures; for this reason the Ames Test became a key 
role in safety assessment [MORTELMANS, 2000].  
 
Within our study, the plate incorporation assay with and without metabolic 
activation was realized in order to analyze the antimutagenic/mutagenic and 
antioxidative/oxidative manner of BR, BV, BRDT and PRO with Salmonella 
tester strains TA 98 and TA 102. 
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3.2. Preparatory work of the Ames Test 
 
3.2.1. Preparatory work of used agar 
 
3.2.1.1. Minimum glucose agar plates 
 
In each 1000 ml Erlenmeyer flask, 11,25g of Oxid agar were dissolved in 700ml 
water. Before autoclaving, the Erlenmeyer flasks were closed with a piece of 
cotton, capped with aluminium foil and indicator tape to ensure, that a 
temperature of 121° Celsius was reached during autoclaving. Along with the 
agar flasks, Pyrex flasks of glucose solution and Vogel-Bonner solution were 
also autoclaved.  
After the sterilization process, the Erlenmeyer flasks were opened under the 
laminar flow and inoculated first with 15 ml Vogel-Bonner solution. After shaking 
37.5 ml glucose solution were added.  
 
Now, the agar was ready-made to pour it in prepared  
sterile Petri-dishes (thickness about 5 mm).  
 
After approximately 12 hours the plates were well dried 
and were repacked in plastic bags and stored at 4° 
Celsius (dated and packed in sealed plastic bags to  
prevent dehydration).  
 
 
3.2.1.2. Top Agar (TA) 
 
1,2 g of Oxiod agar and 1g NaCl was weighed in a Pyrex-flask. The flask was 
then filled to 200 ml with aqua dest. After sterilization, 20 ml of histidine-biotin 
solution was added. After shaking, the top agar was kept warm in a water bath 
under the laminar flow at 48 °Celsius.  
 
Top agar is one of the most critical medium components in the Ames test 
because it contains the trace amount of histidine for limited growth.  
 
Figure 4 Batches of 
poured Petri-dishes 
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3.2.1.3. Master plates Agar (MP) 
 
Master plates were prepared for availability of bacteria. For the preparation of 
two plates, 3.2 g Oxiod agar was dissolved in 200 ml of aqua dest. After 
autoclaving, 4.3 ml Vogel-Bonner- and 10.8 ml Glucose solution were added, 
subsequently, the agar was completed with 2.17 ml of histidine- and 1.3 ml of 
biotin solution. Then, specific antibiotics were pipetted in the cooled-down agar. 
For strain TA 98, the agar was inoculated with 625 µl of ampicillin solution. 
Strain TA 102 furthermore needed 54.3 µl of tetracycline solution. 
 
The mixed agar was filled in Petri-dishes; thickness about 1 cm. After the drying 
process (about 24 hours; laminar switched on) the bacteria solution was spread 
in fine lines onto the agar. When incubation was completed (48 hours at 37 ° 
Celsius) the plates were stored in the refrigerator.  
 
Due to the used antibiotics (Tetracyclin- stable for two weeks; Ampicillin- stable 
for two month) master plates of TA 98 could be used for two months; plates of 
TA 102 could only be stored for two weeks due to the number of spontaneous 
revertant colonies that increases over time.  
 
3.2.2. Preparation of used solutions 
 
3.2.2.1. Preparation of the S9 mix (metabolic activation system) 
 
Bacteria do not have an equivalent metabolic system, like the cytochrome-
based P-450 metablic oxidation system in humans and lower animals. Thus, an 
exogenous mammalian metabolic activation system was included in the test 
procedure in order to imitate the mammalian hepatic metabolisms. 
The used S-9 fraction was prepared from rat liver chemically treated with 
Acrolor 1254.  
 
The S-9 Mix is an enzymatic mixture and contained 19.75 ml of sterile aqua 
dest., 25 ml of PBS (without Ca and Mg), 1 ml of MgCl2/KCl solution, 2 ml of 
NADP solution and 250 µl of glucose-6-posphate solution. The rat homogenate 
was added at last step. The solution was vortexed carefully from time to time.  
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Since the added enzymes are very sensitive, the mixture needed to be cooled 
on crashed ice and prepared freshly each time before starting the test. It could 
be used for a maximum of 60 minutes after opening the flask. 
 
3.2.2.2. Preparation of the Nutrient Broth (NB) and Overnight 
Culture (OVNC) 
 
For cultivating bacteria, 5 g of the Nutrient Broth (weighed into a Pyrex-flask) 
were dissolved in 200 ml of aqua. dest. Subsequently, the flask were capped 
with aluminium foil and indicator tape and transferred into the autoclave.  
 
Before starting the OVNC, specific antibiotics were 
pipetted into the cooled NB. Depending on the used 
tester strains, different amounts of ampicillin and 
tetracycline were inoculated: for TA 98, 625 µl ampicillin, 
for TA 102, 625 µl ampicillin plus 156 µl tetracycline 
were added. 
 
 
Thereof, 12 ml were transferred into a sterile 
Erlenmeyer-flask and inoculated with the adequate 
bacteria strain (swirled through a loop), which were 
scraped off the master plates. The Erlenmeyer-flask was 
closed with a piece of cotton and coated with aluminium 
foil. The OVNC was incubated at 37° Celsius for 12 
hours and shaken continuously at about 100 rpm.  
 
To be on the safe side, OVNC was carried out in duplicate.  
 
 
 
 
 
Figure 6 OVNC- were put in 
incubator 
Figure 5 OVNC 
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3.2.2.3. Preparation of positive and negative controls  
 
Specific positive controls are needed to indicate the reversion of the applied 
bacteria strains. This reversion of bacteria emerges from the reaction of 
bacteria and the added mutagen. 
 
Following chemicals were utilized within test procedure: 
Bacteria strains: 
-S
9
 
TA 98 TA102 
TNFone  TNFone 
 BOOH 
+
S
9
 
AFB₁ +S9 BOOH +S9 
PhIP +S9 AFB₁ +S9 
Table 2 Overview of utilized chemicals and bacteria strains 
 
Negative controls are used in order to display the numbers of spontaneous 
revertants. As a negative control, we used the identical solvent utilized for 
preparing the test samples, but without adding the test substance.  
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Vogel-Bonner solution 
 
The following salts were dissolved one by one in 
670 ml of aqua dest. (45° Celsius): 
- 10 g of magnesium sulphate heptahydrate 
- 100 g of citric acid monohydrate 
- 500 g of dibasic potassium phosphate  
- 175 g of sodium ammonium phosphate 
tetrahydrate 
The solution was autoclaved each time before 
use. 
Glucose solution (40%) 
400 g Glucose was solubilised in 1000 ml of 
heated aqua dest. The solution was autoclaved 
each at time before use. 
Biotin-Histidine solution 
30,9 mg D-biotin and 24 mg L-histidine were 
weighed into a weighing boat, transferred into a 
Pyrex-flask and made up to 250 ml. 
The solution was stored at 4° Celsius and 
autoclaved each time before use. 
Ampicillin solution 
0,2 g of ampicillin is vortexed with 25 ml of 2N 
NaOH; solution was sterilized through an aseptic 
filter and stored at 4° Celsius 
Tetracycline solution 
80 mg of tetracycline was vortexed with 10 ml of 
0,2N HCl; solution was sterilized through an 
aseptic filter and stored at 4° Celsius 
Histidine solution 
0,25 g of histidine was mixed with 50 ml of aqua 
dest.; solution was sterilized through an aseptic 
filter and stored at 4° Celsius 
Biotin solution 
6.1 mg of D-biotion was mixed with 50 ml of aqua 
dest.; solution was sterilized through an aseptic 
filter and stored at 4° Celsius 
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MgCl2/KCl solution 
61.5 g of KCl and 40,7 g of MgCl2 was 
solubilised in 500 ml of aqua dest. and sterilized 
in the autoclave 
NADP solution 
(0,135 g/2ml) 
1 g of NADP was solved in 14.814 ml of aqua 
dest.; solution was sterilized through an aseptic 
filter and kept in portions of 1 ml at -20° Celsius 
Glucose-6-phosphate 
solution (304 mg/ml) 
1 g of glucose-6-phosphate was dissolved in 
3.289 ml of aqua dest.; filter sterilized solution 
kept in portions of 1 ml at -20° Celsius 
Nutrient Broth 
5 g nutrient broth were weighed in into a Pyrex-
flask and filled up with 200 ml aqua dest.; solution 
was autoclaved and inoculated with strain 
specific antibiotics  
Table 3 Index of solutions used within the test procedure 
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Denotation Abbreviation Use 
Aflatoxin B₁ AFB₁ 
Standard mutagen 
(+S9) 
Agar No 1 (Oxoid Agar)  
Plates, 
Top Agar 
Ampicillin Trihydrate  
Master Plates, 
OVNC 
Citric Acid Monohydrate C₆H₈O₇ Vogel-Bonner solution 
D-Biotin C₁₀H₁₆N₂O₃S Master Plates 
D-Glucose C₆H₁₂O₆ 
MG-Agar Plates, 
Master Plates 
Dimethylsulfoxide DMSO Organic solvent 
Glucose-6-phosphate Glu-6-P S9-Mix 
Hydroclorid acid 0,2N HCl Tetracyline solution 
L-Histidine C₆H₉N₃O₂ 
Top Agar, 
Master Plates 
Magnesiumchloride MgCl2 S9-Mix 
Magnesiumsulphate 
heptahydrate 
MgSO₄. 7H₂O Vogel Bonner solution 
Nicotineamid-adeninedinucleotide-
phosphate 
NADPH S9- Mix 
Phosphatebuffer PBS Pre-incubation, S9-Mix 
Potassiumchloride KCl S9-Mix 
Potassiumphosphate, dibasic K₂HPO₄ Vogel-Bonner solution 
Rat liver homogenate S9 
Tests with metabolic 
activation 
Sodiumammonium-phosphate-
tetrahydrate 
Na₂NH₂PO₄. 
4H₂0 
Vogel-Bonner solution 
Sodiumhydroxide 2N NaOH Ampicillin solution 
Tertiary-Butyl-Hydroperoxide t-BOOH 
Standard mutagen  
(+/-S9) 
Tetracycline Hydrochloride  
Master Plates, 
OVNC (+/-S9) 
2-4-7-Trinitro-9-Fluorenone TNFone Standard mutagen 
2-Amino-1-Methyl-6-
Phenylimidazol [4,5-B]Pyridine 
PhIP 
Standard mutagen  
(+/-S9) 
Table 4 Index of chemicals used within the test procedure 
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3.2.3. Bacterial strains used within the test procedure 
 
Within the test procedure, various Salmonella typhimurium tester strains can be 
used. All these bacterial strains have different mutations in the histidine operon, 
which is why they are histidine dependent.  
 
Both bacteria strains (TA 98 and TA 102) used in the study show different 
mutations and alterations in various sections and plasmids in the genes. 
TA 98 carries the hisD3052 mutation which is named frame shift mutation, 
leading to a completely different sequence of bases, resulting in a changed 
sequence of amino acids.  
TA 102 contains the hisG28 mutation which is a transitions/transversions 
mutation. These two types of mutations are categories of so called gene point 
mutations which affect the succession of bases. 
 
3.2.4. Preparation of the test samples  
 
Solubility experiments of BR, BV, BRDT, PRO 
Preliminary, solubility tests were performed in order to gather information on 
solubility - behaviour of these specific bile pigments. The different stock 
solutions were diluted with PBS and Dimethylsulfoxid (DMSO) as organic 
solvent and analyzed photometically at three various time points.  
These pre-tests showed, that the pigments were hardly dissolved, especially 
BR. Therefore, to ensure adequate solubility of the bile pigments, sonication 
was used alongside with gently warming up the samples in a water bath (37°). 
 
3.2.4.1. Preparation operations of uses samples 
 
The samples (BR, BV, BRDT, PRO) were prepared in amber cubs according to 
the scheme of dilution (see table 5) and stored in the freezer in a light-proof 
box. On the day of testing the samples were defrosted and diluted with DMSO 
through a well conceived scheme of dilution. BR was tested in 5 concentrations 
(0.01µmol/plate, 0.05 µmol/plate, 0.1 µmol/plate, 0.5 µmol/plate, 0,75 
µmol/plate), BV, BRDT and PRO were analyzed in 6 concentrations (0.01 
µmol/plate, 0.05 µmol/plate, 0.1 µmol/plate, 0.5 µmol/plate, 1.0 µmol/plate, 2.0 
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µmol/plate). These concentrations were applied to make our study comparable 
with previous research work and particularly to have a concentration area which 
is recommended for the test.   
 
Dilution-scheme 
Sample Stock solution 
(Sample material+ DMSO) 
investigated concentrations (µmol/plate) 
BR 4 mg + 0.274 µl DMSO 0.75 µM 120 µl Stock + 680 µl DMSO 
  0.5 µM 80 µl Stock + 720 µl DMSO 
  0.1 µM 16 µl Stock + 784 µl DMSO 
  0.05 µM 100 µl [0.5 µM] + 900 µl DMSO 
  0.01 µM 100 µl [0.1 µM] + 900 µl DMSO 
    
BRDT 13mg+ 617 µl DMSO 2.0 µM 320 µl Stock + 480 µl DMSO 
  1.0 µM 160 µl Stock + 640 µl DMSO 
  0.5 µM 80 µl Stock + 720 µl DMSO 
  0.1 µM 100 µl [1.0 µM] + 900 µl DMSO 
  0.05 µM 100 µl [0.5 µM] + 900 µl DMSO 
  0.01 µM 100 µl [0.1 µM] + 900 µl DMSO 
    
BV 9mg + 618 µl DMSO 2.0 µM 320 µl Stock + 480 µl DMSO 
  1.0 µM 160 µl Stock + 640 µl DMSO 
  0.5 µM 80 µl Stock + 720 µl DMSO 
  0.1 µM 100 µl [1.0 µM] + 900 µl DMSO 
  0.05 µM 100 µl [0.5 µM] + 900 µl DMSO 
  0.01 µM 100 µl [0.1 µM] + 900 µl DMSO 
    
PRO 9mg + 618 µl DMSO 2.0 µM 320 µl Stock + 480 µl DMSO 
  1.0 µM 160 µl Stock + 640 µl DMSO 
  0.5 µM 80 µl Stock + 720 µl DMSO 
  0.1 µM 100 µl [1.0 µM] + 900 µl DMSO 
  0.05 µM 100 µl [0.5 µM] + 900 µl DMSO 
  0.01 µM 100 µl [0.1 µM] + 900 µl DMSO 
Table 5 Dilution scheme  
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Due to the chemical structure, bile pigments are highly photosensitive.  
In order to avoid any chemical reactions of the substances (e.g. oxidation 
processes), the samples dilution had to be prepared freshly each time before 
starting the test.  
 
3.3. Experimental design 
 
We used the plate incorporation assay procedure according to Ames et al. in 
1973. As compared with the previously used spot test, this procedure provides 
higher sensitivity and is more quantitative  
 
The standard practice is structured in many steps which must be carried out in 
sequential order. It is important to work in a timely manner and to stick to the 
time limits. Therefore a high level of time management is needed in order to 
maintain quality of investigation and to prevent distortion of results. 
 
Before starting the tests, the following preparations had to be performed daily, 
approximately one hour before starting the test procedure: 
 
labeling the minimum glucose agar plates  
(date, sample, concentration, bacterial strain) 
labeling test tubes (sample, concentration): 
- three tubes for each concentration to be examined 
- 6 tubes for negative control 
- 3 tubes for positive control 
preparing dilutions of the samples in the right concentrations according to the 
pipetting scheme 
preparing the positive control 
thawing of the stock solutions  
inoculating the sterilized TA with the biotin-histidine solution 
get the laminar flow ready for the test 
Table 6 Overview of pre- test steps 
 
43 
 
First, TA was ready-made for the autoclave; the next steps were done during 
the period of TA sterilization. 
 
Ready prepared samples as well as sterile equipment (e.g. test tubes, 
Erlenmeyer-flasks, petri dishes) must be available in the laboratory.  
This checkup should already be done some days before a test run is scheduled. 
 
The following scheme illustrates all steps of the Ames Test: 
 
 
Figure 7 Scheme of the Ames Test  
 
In our study, each test was carried out in duplicates (rerun on another day); for 
each concentration three plates were prepared. (total n=6/concentration) 
 
3.3.1. Test procedure in pairs 
 
First of all 500 µl of buffer and 100 µl of bacteria-suspension were alternately 
pipetted, followed by 100 µl of positive control (except negative control tubes) 
and 200 µl of sample. Along with pipetting the first sample, the stopwatch 
(period of twenty-five minutes) was pushed for starting the pre-incubtion period. 
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For the remaining time (after having finished the pipetting), the tubes were 
covered and the whole tube rack was placed in the incubator at 37° Celsius 
(rotary shaker about 100 rpm). Afterwards 2 ml of top agar (kept in the water 
bath at 48° Celsius) was added to each test tube. Then, test tubes were 
vortexed once again and poured onto minimum glucose agar plates and 
stacked in the laminar; after about 20 minutes the plates were well dried and 
placed in the incubator for 48 hours (lid downwards). 
 
Colony counting was started right after the incubation 
period.  
 
For the test with metabolic activation, the S9-mix was 
pipetted instead of the buffer.  
 
3.4. Statistics 
 
Test data was analyzed using SPSS (SPSS Software, Inc., Vers. 16.0) and 
Microsoft Excel (Windows Vista 2009). 
For graphic representation and to calculate arithmetic means and standard 
deviation, raw data were entered into Microsoft Excel.  
Data were tested for normal distribution with the Kolmogorov-Smirnov test. To 
detect possible effects of the bile pigments in revertant growth within different 
concentrations, One-way Analysis of Variance (ANOVA) was selected. For post 
hoc evaluation the Bonferroni and Scheffé test was realized. For testing 
homogenous subsets, the Tukey test was used. 
Significant level for statistical analysis was considered at p< 0.05. 
 
Following published criteria of Mortelmans et al. (2000) were further used to 
interpret our results:   
- Mutagenic:  
A compound was classified as mutagenic, if test procedure showed a 
concentration dependency and further, when the numbers of his+ revertant 
colonies were higher than double negative values. 
Figure 8 Counted MG-
Plates 
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- Weak mutagenic: 
Substances were identified as weak mutagenic when the numbers of his+ 
revertant colonies were not exceeded double negative values, but a 
concentration dependency was demonstrated. 
- Non-mutagenic: 
If no concentration dependency could be proven within test procedure, samples 
were rated as not mutagenic.  
- Anti-mutagenic 
If the relative mutagenic response fell below 50 percent, substances were 
classified as anti-mutagenic.  
- Inconclusive: 
If compounds cannot be clearly interpreted as mutagen or nonmutagen, the 
results were discussed as inconclusive.  
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4. RESULTS AND DISSCUSSION 
 
To detect the possible antimutagenic and antioxidative effects of BR, BV; BRDT 
and PRO, tester strains were used in order to achieve selective information 
about frameshift mutations (TA 98) and data about oxidative stress (TA 102).  
The following table shows the mutagens which were used within the test 
procedure:  
 
 
Anti-mutagenic/ anti-oxidative test procedure in the Salmonella 
Ames assay: 
TA 98 TA 102 
AFB₁ 0.8*10-7 µmol/plate + S9 AFB₁ 0.24*10-6 µmol/plate + S9 
TNFone 0.3*10-6 µmol/plate TNFone 0.2*10-7 µmol/plate 
PhIP 0.1*10-7 µmol/plate + S9 t-BOOH 0.75*10-6 µmol/plate 
 t-BOOH 0.75*10-6 µmol/plate +S9 
Table 7 Overview of used mutagens and bacterial strains  
 
After the practical procedure in the lab and manual colony counting, statistical 
analysis was performed. The following chapter gives an overview of obtained 
results.  
 
A detailed overview of all counted single revertant numbers is shown in chapter 
nine (Appendix). 
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4.1. Antimutagenic Testing 
 
4.1.1. TA 98 
 
4.1.1.1. Mutagenicity induced by PhIP 0.1 µmol/ml + S9 
 
In this condition, BR, BV, BRDT and PRO were tested in the presence of 
metabolic activation.  
 
 
Figure 9 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on PhIP induced mutagenicity in TA 98 
 
Figure nine shows that all tested substances were able to reduce PhIP induced 
mutagenicity. All compounds passed the 50 percent line. 
PRO was the compound yielding the most pronounced antimutagenic effect. 
Less than 10% of the induced colonies were still countable, which means that 
more than 90% were inhibited. Highly significant reductions of His+revertants 
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became obvious when all tested concentrations of BR, BV, BRDT and PRO 
were compared to the positive control (p<0.01).  
BV and PRO inhibited PhIP induced mutagenicity in a dose-dependent manner 
as depicted in figure 10: 
 
Figure 10 Colony counts after incubation with BV (left) and PRO (right), tested in TA 98 
with PhIP +S9; (positive control= 100%); * significantly different from positive values 
 
All six tested concentrations (2.0; 1.0; 0.5; 0.1; 0.05; 0.01) of BV and of PRO, 
showed highly significant reductions of colony counts compared to the positive 
control (p<0.01). More precisely, BV yielded a difference in statistical 
significance (p<0.05) between all tested concentrations, except concentration 
BV 0.05 to BV 0.01. A highly significant difference became obvious between the 
highest (2.0) and the lowest (0.01) concentration of BV (p<0.01); so, the 2.0 
concentration was more efficient in inhibition of colony formations than the 0.01 
dose. The same was true for PRO (p< 0.01). Significant differences were also 
observed between PRO 0.1 to 0.05 and PRO 0.05 to 0.01 (p<0.05). 
 
The ID₅₀ for BV of 0.011 µmol/ml was respectably low, which means that 0.011 
µmol/ml were required for a 50 percent inhibition of the mutagenic response of 
PhIP.  
 
* 
* 
* 
* * 
* * * * * * 
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Homogeneity of variance was tested within the Tukey test. All tested 
concentrations of BR, BRDT and PRO showed heterogenic tendences 
compared to the positive control.  
 
4.1.1.2. Mutagenicity induced by TNFone 0.0001 mg/ml 
 
In the absence of metabolic activation BR, BV, BRDT and PRO were tested 
with the standard mutagen TNFone. 
 
 
Figure 11 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on TNFone induced mutagenicity in TA 98 
 
Test results indicated antimutagenic trends for all tested substances. BR (0.75; 
0.5) and BRDT (2.0; 1.0) passed the 50 percent line, as well as all tested 
concentrations of PRO. Highest tested doses of PRO (2.0; 1.0) inhibited more 
than 90 percent of TNFone´s induced mutagenicity and showed a clearly 
antimutagenic effect. BV showed the smallest potential tendencies.  
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Compared to the positive control, BR 0.75 and 0.5 were significantly lower 
(p<0.01; p<0.05); BRDT 2.0 differed also significantly from the positive control 
(p<0.05), as well as BRDT 1.0 (p<0.01). PRO depicted highly significant 
reductions of His+revertants in each tested concentration compared to the 
positive control (p<0.01). For BV, there was no significant outcome.  
Test results of BR, BRDT and PRO exerted a dose dependent impact on 
TNFone: 
 
 
Figure 12 Colony counts after incubation with BR (orange), BRDT (red) and PRO (blue) 
tested in TA 98 with TNF one; (positive control= 100%) * significantly different from 
positive values 
 
Comparing the highest (0.75) with the lowest (0.01) tested concentration of BR, 
a highly significant difference was observed (p<0.01); this means that the 
highest concentration was more efficient in inhibition His+revertants after 
incubation than the lowest tested dose. The same was true for BRDT (2.0 vs 
0.01; p< 0.05) and PRO (2.0 vs. 0.01; p<0.05).  
 
Especially for BR the ID₅₀ with 0.153 µmol per plate was remarkably low; for 
BRDT, the ID₅₀ was about three times higher with 0.434 µmol per plate. That 
implies that two third more BRDT is required to reach the 50 percent inhibition 
of the mutagenic response of TNFone.  
* 
* * 
* * 
100% 
50% 
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Within testing homogeneity of variance, BR depicted heterogeneity in the doses 
0.75 and 0.5 compared to the positive control. BRDT showed a difference 
compared to the positive control in the concentrations 2.0 and 1.0. For PRO 
heterogeneity of variances can be considered for all tested concentrations 
compared to the positive control. 
 
4.1.1.3. Mutagenicity induced by AFB₁ 35µg/ml + S9 
 
In the presence of metabolic activation and AFB₁, all compounds (except PRO) 
showed a non expected increase of mutagenicity.  
 
Figure 13 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on AFB₁ induced mutagenicity in TA 98 
 
Each of the Ames Test trials was repeated two times on different lab days. In 
total, the test results of TA 98 induced mutagenicity by AFB₁ are uncommonly 
high and indefinably pronounced increase of mutagenicity in the presence of 
S9. Similar results cannot be found in literature.  
Nevertheless, repetitions of the approach confirm these surprisingly high 
values.  
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Previously Bulmer et al. (2007) tested BR, BRDT and BV in the absence of 
metabolic activation and confirmed that all tested compounds inhibited the 
TNFone induced mutagenicity in a dose dependent manner.  
 
Similar results were shown in our study. We confirmed antimutagenic 
tendencies in all 4 tested substances (BR, BRDT, BV, PRO) while BV showed 
the lowest and PRO the highest effect. Compared to the study of Bulmer et al., 
BR and BR-DT equally exerted a dose dependent impact on TNFone. However, 
a dose dependent manner of BV was not confirmed in our study.  
Taken these two studies together, data support the hypothesis of an 
antimutagenic potential of BR, BRDT; for BV, a great antimutagenic trend was 
confirmed. Due to the fact, that PRO has been not tested before; more studies 
will be needed in the future to reaffirm these results, however, PRO showed the 
most promising results.  
 
Bulmer et al. (2007) also tested the mutagens 2-aminofluorene (2- AF, which is 
found in the cooking process) and benzo [a]pyrene (B[a]P belongs to the group 
of mutagens induced from combustion) in the presence of S9 and found for BR, 
BRDT and BV antimutagenic effects. Especially, against B[a]P, all substances 
showed a dose dependent reduction of colony formation. Romert et al. (1994) 
and Camoirano et al. (1994) also tested bile pigments in the test in the 
presence of S9 and found antimutagenic effects against cigarette smoke (CS), 
a cigarette smoke condensate (CSC) and 4-nitropunoline-1-oxide (4NQO, a 
mutagen derived from the processes of combustion).  
 
The results of Arimoto et al. (1980) also confirmed antimutagenic effects of bile 
pigments in the Ames test, tested against B[a]P and concluded that BR was 
more effective than BV. A further study of Arimoto et al. in 1995 showed weak 
antimutagenic effects of BR and BV against B[a]P metabolites.  
 
However, the recently published study of Bulmer et al. (2007) presented 
oppositional data: BV was the most effective pigment in the same condition as 
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mentioned above. The theory that among this condition, pigments are capable 
of directly binding to B[a]P is speculative. Since data are limited on B[a]P and 
bile pigments clear mechanistic conclusions cannot be drawn [BULMER et al., 
2008].  
 
Data on the anti-mutagenic behaviour of bile pigments against AFB₁ and PhIP, 
two mutagens which are formed after processing or cooking of foods, were not 
found in Ames Test specific literature; for instance a recently published study of 
Mosovska et al. (2010) investigated gentoxic and antimutagenic acitivities of 
extracts of pseudocereals in the Ames Test and came to the result that extracts 
of amaranth, sorghum and Japanese millet were effective to inhibit the 
mutagenic response to AFB₁. Several studies on the behaviour of AFB₁ were 
also published in cell studies, therefore, in the future, according to the literature 
currently available, mechanistic studies along the field of bile pigments are 
needed. 
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4.1.2. TA 102 
 
4.1.2.1. Mutagenicity induced by AFB₁ 100µg/ml +S9 
 
Antimutagenic effects of BR, BV, BRDT and PRO were tested against AFB₁ in 
the presence of metabolic activation.  
 
Figure 14 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on AFB₁ induced mutagenicity in TA 102 
 
The inhibition curves of all pigments passed the 50 percent line, except BR 
0.01, BV 0.5 and BV 0.05. Therefore a highly antimutagenic effect was 
observed in this approach. Again the greatest antimutagenic effect was clearly 
showen by PRO in all tested concentrations as demonstrated in figure 14.  
Compared to the positive control, a highly significant reduction of colony 
formation of all tested concentrations of BR, BV, BRDT and PRO was observed 
(p<0.01).  
In the Tukey- test, all tested concentrations of BR, BV, BRDT and PRO showed 
heterogenic variances compared to the positive control. 
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4.1.2.2. Mutagenicity induced by TNFone 0.07 mg/ml 
 
Since TNFone needs no activation, BR, BV, BRDT and PRO were tested 
without addition of the rat liver homogenate. 
 
Figure 15 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on TNFone induced mutagenicity in TA 102 
 
All four compounds illustrated antimutagenic effects within the test regimen. 
Highest tested concentrations of BR (0.75; 0.5; 0.1), BV (2.0) and BRDT (2.0; 
1.0; 0.5) passed the 50 percent line. Once more, PRO was the most effective 
substance; all tested concentrations passed the 50 percent line and were 
observed to prevent TNFone- induced mutagenicity, as depicted in figure 15.  
 
All tested concentrations of BR, BRDT and PRO were very effective in reducing 
His+ revertants and showed highly significant reductions compared to the 
positive control (p<0.01). For BV, only the 0.05 concentration was not 
significantly different.  
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Within testing homogeneity of variance, heterogeneity of variances was 
considered for all tested concentrations of BR, BV, BRDT and PRO. 
 
Equal to our study, the recently published study of Bulmer et al. (2007) 
examined TNFone induced mutagenicity in TA 102 related to BR, BRDT and 
BV. The results of Bulmer et al. showed that all tested bile pigments were 
antimutagenic in a dose dependent manner. Compared to our study, similar 
effects were detected and assumed antimutagenic effects in these series of 
tests were reconfirmed. All of our tested pigments (BR, BV, BR-DT and PRO) 
passed the 50 percent inhibition line. 
Thus we can conclude that within our study we can confirm results by Bulmer et 
al. (2007) in their studies and, we contribute to the evident positive potential of 
these colourful compounds.  
 
In our present study, a further series of tests were performed against the 
mutagenicity of AFB₁+S9 with the result of highly antimutagenic potential of BR, 
BV, BRDT and PRO. All substances passed the 50 percent inhibition line with 
highest effects for PRO.  
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4.2. Antioxidative Testing 
 
4.2.1. TA 102 
 
4.2.1.1. Antioxidative effects in tests with t-BOOH 0.75*10^-6 
µmol/plate 
 
In the presence and absence of metabolic activation, BR, BV, BRDT and PRO 
were tested for their efficacy to prevent oxidative damage induced by t-BOOH 
(see figure 16). 
Without enzymatic activation, all four compounds showed an antioxidative 
trend; moreover PRO was able to pass the 50 percent inhibition line at the 
highest concentration tested.  
 
 
Figure 16 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PRO) on t-BOOH induced antioxidativity in TA 102 
 
Compared to the positive control, a highly significant reduction (p<0.01) of BV 
and BRDT was observed in following concentrations: 2.0; 1.0; and 0.5. 
PRO reduced highly significant the numbers of His+revertants in all six tested 
concentrations (p<0.01), except the lowest one of 0.01.  
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Under this condition, BRDT and PRO inhibited the t-BOOH induced oxidation in 
a dose-dependent manner as seen in the figures below: 
  
Figure 17 Colony counts after incubation with BRDT (red) and PROT (blue) in TA 98 with 
t-BOOH; (positive control=100%)* significantly different from positive values 
 
For both compounds the 2.0 concentration was significantly more efficient than 
the lowest concentration of 0.01 (p<0.01). Compared to the positive control 
tested homogeneity of variance showed significant values for BV and BRDT in 
concentrations 2.0, 1.0 and 0.5, as well for BRDT 0.1. PRO showed significant 
differences in all tested concentrations.  
 
4.2.1.2. Antioxidative effects in tests with t-BOOH 0.75*10^-6 
µmol/plate +S9 
 
When metabolic activation was applied, the pigments lost their antioxidant 
effects. BRDT, BV and PRO showed an increase in the number of mutants and 
exceeded the 50 percent line.  
PRO was the compound with the highest increase; all tested concentrations 
passed the 100 percent line, except the 0.01 concentration. PRO 1.0 was more 
than 20 percent higher than the positive control. No effect was shown for BR. 
* * * 
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Figure 18 The modulatory effects of bilirubin (BR), biliverdin (BV), bilirubin-ditaurate 
(BRDT) and protoporphyrin (PROT) tested with t-BOOH + S9 
 
Only BV 0.1 showed significant differences to the positive control (p<0.05).  
No significant differences of BR, BRDT and PRO were found.  
 
Bulmer et al. (2007) investigated the potential of BR, BV and BRDT in reducing 
t- BOOH induced oxidation in TA 102. This study was a premiere; investigating 
the effects of bile pigments under such condition has never been done before 
according to literature. The outcome was that BR and BV showed a dose-
dependent inhibitory effect of mutagenicity in the absence of the rat liver 
homogenate; for BRDT, no effect was confirmed.  
However, the here presented findings differ from the study of Bulmer et al. 
(2006). Our results showed that all tested substances (BR, BV, BRDT, PRO) 
indicated an antioxidative trend, BRDT and PRO in a dose dependent manner. 
But only PRO showed the clearest antioxidant effect and passed the 50 percent 
inhibition line at all tested concentrations in the TA 98 test against induced 
mutations of PhIP and TNFone, as well in the TA 102 test against induced 
mutagenicity of AFB₁ and TNFone.  
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Bulmer et al. (2007) also investigated antioxidative effects in the presence of 
metabolic activation and similar results were found. Summing up the results of 
Bulmer et al., BR and BV inhibited mutagenicity induced by t-BOOH in a dose 
dependent manner; BRDT showed no effect. These findings were contrary to 
our results, because we found no antioxidative effect in this approach 
 
Due to the fact that the study of Bulmer et al. (2007) and the here presented 
study found different results, further research work is needed to fill the lack of 
knowledge and to produce clearly evidenced data in the future.  
 
4.3.  Concluding considerations of antimutagenic/ antioxidative testing 
 
Bulmer et al. (2008) reviewed in their paper that the antimutagenic effects of 
bile pigments were mainly dependent on the tested mutagen. 
 
Tables 8-10 are summarizing our findings of TA 98 and TA 102: 
 AFB₁ 
(+S9) 
TNFone 
PhIP 
(+S9) 
Bilirubin - ↓ - 
Biliverdin - - ↓↓↓ 
Bilirubin- 
ditaurate 
- ↓ - 
Protoporphyrin - ↓↓↓ - 
- ID50 not calculable 
 ↓ 50% inhibition of positive control at 2.0 μmol/plate 
 (0.75 µmol/plate for BR) 
 ↓↓ 50% inhibition of positive control between 1.0 and 
 0.1μmol/plate and at 0.01 μmol/plate 
 ↓↓↓ 50% inhibition of positive control at each tested 
 concentration 
Table 8 Modulatory effects of bilirubin, biliverdin, bilirubin-ditaurate, protoporphyrin in 
Salmonella typhimurium strain TA98 
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 AFB₁ 
(+S9) 
TNFone 
t-BOOH 
(-S9) 
t-BOOH 
(+S9) 
Bilirubin - ↓ - ↑ 
Biliverdin ↓ - - - 
Bilirubin- 
ditaurate 
- ↓ - - 
Protoporphyrin - ↓↓↓ ↓ ↑ 
  
  - ID50 not calculable 
 ↓ 50% inhibition of positive control at 2.0 μmol/plate 
 (0.75 µmol/plate for BR) 
 ↓↓ 50% inhibition of positive control between 1.0 and 
 0.1μmol/plate and at 0.01 μmol/plate 
 ↓↓↓ 50% inhibition of positive control at each tested 
 concentration 
 ↑ no inhibition of positive control 
 
Table 9 Modulatory effects of bilirubin, biliverdin, bilirubin-ditaurate and protporphyrin in 
Salmonella typhimurium strain TA102 
 
Due to the weak solubility of bile pigments in the lab, Bulmer et al. (2007) 
suggested that it would be worth to try albumin-bound BR instead of BR alone. 
Albumin-bound BR is a more water-soluble complex which makes it easier to 
investigate higher concentrations of BR.  
 
Evidently, in both series of tests in TA 98 and TA 102 PRO showed the highest 
antimutagenic effects, almost always in a dose dependent manner. These 
results should be seen as a motivation for researchers to investigate this 
substance more detailed in future.  
 
Finally, the following table shows our results, for the ID ₅₀ and ID₀.₇₅ inhibition:  
Strain Mutagen S9 Compound ID ₅₀ 
(µmol/plate) 
ID ₀.₇₅ 
(%) 
TA 98 PhIP 0.1µmol/ml + BR - 36 
   
BV 0.011 19 
   
BRDT - 32 
   
PROT - 32 
TA 98 TNF one 0.0001 mg/ml - BR 0.153 31 
   
BV - - 
   
BRDT 0.434 46 
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PROT 0.000010 9 
TA98 AFB₁ 35 ug/ml + BR - - 
   
BV - - 
   
BRDT - - 
   
PROT - - 
TA 102 AFB₁ 100 µg/ml + BR - 46 
   
BV 0.184 47 
   
BRDT 
 
43 
   
PROT 
 
32 
TA 102 TNF one 0.07 mg/ml - BR 0.216 38 
   
BV - - 
   
BRDT 0.096 46 
   
PROT 0.00012 25 
TA 102 
BOOH 0.75*10^-6 
µmol/plate 
- BR - - 
   
BV - - 
   
BRDT - - 
   
PROT 1.119 57 
TA 102 
BOOH 0.75*10^-6 
µmol/plate +S9 
+ BR 0.223 - 
   
BV - - 
   
BRDT - - 
   
PROT 0.00020 - 
Table 10 The modulatory effects of BR (bilirubin), BV (biliverdin), BRDT (bilirubin-
ditaurate) and PROT (protoporphyrin) on genotoxicity in TA 98 and TA 102 Salmonella 
typhimurium strains. ID ₅₀, dose of compound required for 50% inhibition;  
ID ₀.₇₅, percent inhibition at 0.75 µmol/plate 
 
4.4. Mutagenic Testing 
 
Mutagenic testing was performed in order to support our tested anitmutagenic/ 
antioxidative results of BR, BV, BRDT and PRO and further to investigate 
whether the tested bile pigments do have mutagenic activity. The test procedure 
was identical to the antimutagenic test series, except that no positive control 
was added to the test tubes. 
In general, it can be concluded, that all results in the mutagenic testing 
procedure were nearby the 100 percentage line. Neither significant increases 
nor obvious reductions were observed after testing the mutagenicity/oxidative 
behaviour of these compounds. 
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A comprehensive overview about all tested values and counted single revertant 
numbers are listed in chapter nine (Appendix). 
 
4.4.1. TA 98 
 
Within the test procedure, BR, BV, BRDT and PRO were tested against the 
mutagens PhIP, TNFone and AFB₁.  
For all mutagens, all tested compounds were highly significant lower than the 
double negative control (p<0.01).  
 
4.4.2. TA 102 
 
Bacterial strain was tested against TNFone, AFB₁ +S9 and t-BOOH with and 
without metabolic activation. Equally to the mutagenic testing in TA 98, for all 
mutagens, all tested compounds were significantly lower compared to the 
double negative control (p<0.01).  
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5. CONCLUSION 
 
In general, the area of bile pigments is a relatively new field of research which 
became more and more attractive in the last two decades. Although published 
data is still rare, the theory of a physiological relevance of bile pigments is 
growing in the past years with the suggestion that bile pigments possess 
preventative potential, including anti-complement, anti-inflammatory anti-viral, 
antimutagenic and antioxidative properties, as well antioxidative capacity 
towards oxidation of lipids and proteins [BULMER et al., 2008].  
The thesis at hand deals with the potential protective and beneficial role of bile 
pigments and is especially focused on the theory of possible antimutagenic and 
antioxidative properties of bilirubin, biliverdin, bilirubin-ditaurate and 
protoporphyrin. In recently published studies (e.g. BULMER, 2008; BULMER et 
al., 2007; STOCKER, 2004), these antimutagenic and antioxidative effects of 
bile pigments were already found.  
 
Aim of this thesis was to support these effects. Therefore, the Salmonella Ames 
test was used as test model, which is a popular method to detect relative simply 
mutagens/antimutagens. Antimutagenic and antioxidative properties of bilirubin, 
biliverdin, bilirubin-ditaurate and protoporphyrin were tested in different 
concentrations (2.0- 0.01) with selected groups of mutagens (TNFone, PhIP, t-
BOOH, AFB₁) in presence and absence of metabolic activation. For the test 
procedure, Salmonella typhimurium indicator strains TA 98 and TA 102 were 
used. The experiments were aimed to investigate antimutagenic properties in 
both tester strains; possible antioxidative properties were investigated with and 
without the S9 mix by using TA 102 as tester strain for t-BOOH induced 
oxidative mutations.  
 
In general, our test results showed different antimutagenic and antioxidative 
effects and tendencies in both bacterial strains. Therefore, we were able to 
confirm the theory of the antimutagenic and antioxidative potential of these 
specific bile pigments.  
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Reconsidering the test series with TA 98 against PhIP and TNFone induced 
mutagenicity, there is every indication of antimutagenic effects in both test. All 
four substances significantly inhibited PhIP induced mutagenicity compared to 
the positive control in all tested concentrations, PRO and BV in a dose 
dependent manner. The TNFone test resulted in a significant reduction of 
His+revertants of all PRO concentrations. The same significant reduction was 
true for highest tested doses of BR (0.75; 0.5) and BRDT (2.0; 1.0). A dose-
dependency was shown for BR, BRDT and PRO. Under this condition we could 
confirm published data of Bulmer et al. (2007) because they showed as well a 
dose dependent manner of BR and BRDT against TNFone induced 
mutagenicity. Taken these two tests together, the greatest antimutagenic effect 
was observed by PRO, which passed plainest the 50 percent inhibition line. 
Since similar tests of PRO of this condition could not be found in literature, 
further test series are needed to confirm these promising results.  
Unexpected and uncommonly high values were shown in the TA 98-test against 
AFB₁ in presence of metabolic activation. This non expected increase in 
mutagenicity was confirmed in two test reruns. Comparable results cannot be 
found in literature. Results of test procedures with bacterial strain TA 102 
against AFB₁+S9 and TNFone induced mutagenicity suggested also 
antimutagenic effects. Compared to the positive control, all four test substances 
showed significant reductions of His+revertants in the test series against AFB₁ 
induced mutagenicity. The same was true for BR, BV (except the 0.05 
concentration) and PRO in the TNFone test. Interestingly, ineffectiveness of test 
samples became apparent in the TA 102-test with t-BOOH+S9, while the test 
without metabolic activation showed antioxidative trends of all compounds. 
Therefore we can conclude that the S9 mix has an effect on bile pigments to 
neutralize antioxidative effects.  
 
These findings give interesting insights in possible modes of action of bile 
pigments, but no clear statement about the impact in the living organism can be 
made. Our findings can be considered as important observations contributing to 
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the indicated possible protective physiological role of bile pigments and the 
understanding and the mechanism behind the bile pigments. 
In future, it must be the aim to stimulate further research work in this area to 
confirm already published studies and to gain information of the functionality of 
bile pigments more detailed. The clinical use of BR as a possible therapeutical 
agent to prevent several diseases is imaginable and must be the long-time 
objective for scientists. 
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6. SUMMARY 
 
The objective of the present sub-study of an FWF project was to investigate 
possible antimutagenic and antioxidative effects of bile pigments.  
The Salmonella /microsome mutagenicity assay was used as well established 
model to identify mutagenic potential of chemicals and drugs.  
 
Biliverdin, bilirubin-ditaurate and protoporphyrin were tested in six (2.0; 1.0; 0.5; 
0.1; 0.05; 0.01), BR was used in five (0.75; 0.5; 0.1; 0.05; 0.01) concentrations 
in the presence and absence of S9. Different groups of mutagens were used 
(TNFone, AFB₁ and PhIP) as known mutagens to test the antimutagenic 
potential of these selected pigments; t-BOOH was used to gain information 
about their antioxidative potential.  
In general, our results indicate that all substances possess antimutagenic 
properties in the chosen range of concentrations, except mutagenicity induced 
by AFB₁ in the bacterial strain TA 98 which showed an uncommonly and 
indefinably pronounced increase of mutagenicity in the presence of S9. 
More precisely, all four compounds tested with PhIP+ S9 and TNFone showed 
antimutagenic tendencies and effects. The highest effect was clearly apparent 
in PRO. In both experiments all four tested substances were able to reduce the 
induced mutagenicity. Antioxidative effects of all four compounds were 
confirmed tested against t-BOOH. In the presence of metabolic activation, 
interestingly, no effect was observed in all of the tested pigments. 
 
To conclude, our results showed considerable antimutagenic and antioxidative 
effects, trends and tendencies. Therefore our results contribute to the theory 
that bile pigments possess positively modulating and beneficial properties in 
vitro. Our findings recommend further research work to get more detailed 
information on the preventative potential of bile pigments.  
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7. ZUSAMMENFASSUNG 
 
Ziel der vorliegend Arbeit war es, die möglichen antimutagenen und 
antioxidativen Eigenschaften von Gallenfarbstoffe zu untersuchen und zu 
beweisen.  
 
Als Methode wurde der Ames Test gewählt, ein international einheitliches, 
anerkanntes und populäres Testverfahren um Chemikalien, Pharmaka und 
Biozide hinsichtlich ihres anti-mutagenen/anti-oxidativen Potentials zu 
bewerten. Analysiert wurden die Substanzen Bilirubin, Biliverdin und Bilirubin-
Ditaurat, ein synthetisches wasserlösliches Bilirubinconjungat, sowie 
Protoporphyrin, eine Vorläufersubstanz von Häm, mit und ohne metabolische 
Aktivierung in unterschiedlichen Konzentrationen. Biliverdin, Bilirubin-Ditaurat 
und Protoporphyrin wurden in sechs verschiedenen Konzentrationen getestet 
(2.0; 1.0; 0.5; 0.1; 0.05; 0.01), Bilirubin wurde in fünf verschiedenen 
Konzentrationen untersucht (2.0; 1.0; 0.5; 0.1; 0.05; 0.01).  
Zu Analysezwecken kamen 2 verschiedene Bakterienstämmen von Salmonella 
typhimurium zum Einsatz. Als Mutagene wurden 2-4-7 trinitrofluenon (TNFone), 
Tertiär-Butylhydroperoxid (t-BOOH), Aflatoxin B₁ (AFB₁) und 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP) gewählt.  
 
Zusammengefasst lieferten die Tests folgende Resultate: 
Alle vier getesteten Substanzen zeigten in den TA 98 Tests mit PhIP und 
TNFone+S9 deutliche antimutagene Wirkung. Portoporphyrin zeigte in beiden 
Experimenten die stärksten antimutagenen Aktivitäten. Als deutlich mutagen im 
TA 98 Test erwies sich jedoch AFB₁+S9. Trotz mehrmaliger Wiederholung 
dieser Testreihe bestätigten sich überraschenderweise diese ungewöhnlich 
hohen Werte. Weitere Analysen bestätigten ebenfalls das antimutagene 
Potential der getesteten Substanzen. In TA 102 Testreihen mit AFB₁+S9 und 
TNFone zeigten alle Substanzen antimutagene Tendenzen und Effekte. 
Protoporphyrin zeigte abermals die stärksten antimutagenen Effekte.  
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Die antioxidativen Eigenschaften der Testsubstanzen wurde mit dem Mutagen 
t-BOOH mit und ohne metabolische Aktivierung untersucht. Konträre Resultate 
konnten beobachtet werden; während alle Substanzen ohne metabolische 
Aktivierung antioxidative Wirkung zeigten, waren in Testreihen mit 
metabolischer Aktivierung alle Substanzen inaktiv.  
Zusammengefasst kann man sagen, dass diese Studie antimutagene und 
antioxidative Tendenzen und Effekte der Gallenfarbstoffe bestätigt hat. Um die 
physiologische Rolle sowie das Verständnis und die Funktionalität der 
Gallenfarbstoffe in Zukunft besser beurteilen zu können sind weitere 
Experimente auf diesem Gebiet sinnvoll um auch bereits bewiesene protektive 
Fähigkeiten der Gallenfarbstoffe zusätzlich zu bekräftigen.   
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9. APPENDIX 
 
9.1. Antimutagenicity tests with TA 98 
 
9.1.1. Single revertant numbers: TA 98 + TNFone 0.3*10-6 µmol/plate 
 
Table 11 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
1
5
.4
.0
9
   84 116 192 232 277 
  74 106 220 223 240 
  80 103 217 228 260 
A
s
s
a
y
 I
I 
2
2
.4
.0
9
   51 54 83 111 126 
  51 56 104 118 106 
  40 85 89 125 108 
mean   63 87 151 173 186 
 sd   18.3 26.5 65.5 60.3 80.9 
B
V
 A
s
s
a
y
 I
 
1
5
.4
.0
9
 248 159  286 211 203 211 
198 197  260 241 218 206 
153 214  210 212 225 188 
A
s
s
a
y
 
II
 
2
2
.4
.0
9
 81 89  61 95 120 100 
79 82  101 114 117 134 
62 98  76 100 96 120 
mean 137 140  166 162 163 160 
 sd 75.4 58.0  98.5 66.0 58.2 47.7 
B
R
-D
T
 
A
s
s
a
y
 I
 
1
5
.4
.0
9
 137 149  153 226 209 235 
105 127  201 203 230 227 
138 135  175 187 219 240 
A
s
s
a
y
 
II
 
2
2
.4
.0
9
 65 67  106 93 96 118 
60 73  80 97 121 128 
57 81  56 113 100 100 
mean 94 105  129 153 163 175 
sd 38.1 35.7  56.8 58.9 63.2 65.7 
P
R
O
T
 
A
s
s
a
y
 I
 
1
5
.4
.0
9
 11 16  17 25 18 30 
12 17  21 25 23 36 
14 17  22 20 16 28 
A
s
s
a
y
 
II
 
2
2
.4
.0
9
 18 18  35 49 55 107 
17 24  33 48 63 107 
19 27  44 49 64 98 
mean 15 20  29 36 40 68 
sd 3.3 4.5  10.3 14.0 23.1 40.0 
 mean sd 
Pos 285/306/303/200/192/195 247 11.4 
Neg 21/27/24/20/21/21/23/22 22 2.8 
2xneg  42/54/48/40/42/42/46/44 44 5.5 
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9.1.2. Single revertant numbers: TA 98 + AFB₁ 0.8*10-7 µmol/plate +S9 
 
Table 12 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
2
3
.6
.0
9
   1696 1797 1682 1573 1313 
  1794 1884 1427 1595 1567 
  1763 1767 1752 1503 1736 
A
s
s
a
y
 I
I 
6
.7
.0
9
   1244 1549 1260 1160 1730 
  1462 1488 1779 956 1702 
  1316 1000 1412 1146 1761 
mean   1546 1581 1552 1322 1635 
 sd   237.6 322.6 214.0 268.9 172.0 
B
V
 A
s
s
a
y
 I
 
2
3
.6
.0
9
 921 1700  1677 1457 1464 1563 
975 1645  1664 1637 1937 1564 
861 1510  1631 1992 1214 1542 
A
s
s
a
y
 
II
 
6
.7
.0
9
 1106 1250  1275 1728 1601 1632 
974 1517  1322 1384 1826 1547 
1130 1432  1636 1381 1760 1454 
mean 995 1509  1534 1597 1634 1550 
 sd 104.7 160.0  183.9 239.3 264.9 57.2 
B
R
-D
T
 
A
s
s
a
y
 I
 
2
3
.6
.0
9
 1075 1175  1433 1396 1547 1434 
817 1214  1527 1354 1673 1562 
924 1189  1484 1233 1654 1498 
A
s
s
a
y
 
II
 
6
.7
.0
9
 1107 1106  1678 1047 1309 1317 
819 960  1179 974 1061 1012 
858 974  1246 1467 1316 1165 
mean 933 1103  1425 1245 1427 1331 
sd 128.5 111.4  184.7 198.4 239.4 210.4 
P
R
O
T
 
A
s
s
a
y
 I
 
2
3
.6
.0
9
 264 258  358 399 521 458 
341 389  250 352 245 398 
442 254  353 383 563 528 
A
s
s
a
y
 
II
 
6
.7
.0
9
 462 337  242 365 287 353 
391 323  148 358 275 418 
157 323  108 332 254 345 
mean 343 314  243 365 358 417 
sd 115.9 51.1  102.6 23.6 144.3 68.8 
 mean sd 
Pos 304/354/332/326/367/364/ 341 24.7 
Neg 36/39/46/39/36/33/27/39/31/31/43/ 36 5.4 
2xneg 72/78/92/78/72/66/54/78/62/62/86 73 10.7  
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9.1.3. Single revertant numbers: TA 98 + PhIP 0.1*10-7 µmol/plate +S9 
 
Table 13 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
1
5
.6
.0
9
   405 510 542 449 377 
  385 383 368 379 370 
  510 380 343 380 378 
A
s
s
a
y
 I
I 
1
6
.6
.0
9
   497 366 313 349 395 
  363 354 615 379 580 
  367 379 361 376 390 
mean   421 395 424 385 415 
 sd   65.6 57.2 123.6 33.4 81.3 
B
V
 A
s
s
a
y
 I
 
1
5
.6
.0
9
  162  228 238 493 496 
117 150  248 350 469 487 
135 149  255 533 494 490 
A
s
s
a
y
 
II
 
1
6
.6
.0
9
 123 166  218 312 826 506 
132 183  275 437 390 573 
165 186  263 325 526 590 
mean 134 166  248 366 533 524 
 sd 18.5 15.8  21.5 104.1 150.7 45.6 
B
R
-D
T
 
A
s
s
a
y
 I
 
1
5
.6
.0
9
 259 374  473 367 405 369 
337 306  369 356 304 320 
295 443  418 343 318 325 
A
s
s
a
y
 
II
 
1
6
.6
.0
9
 293 370  483 333 472 362 
330 424  480 298 444 279 
354 367  533 424 366 340 
mean 311 381  459 354 385 333 
sd 35.1 48.3  57.4 41.9 67.6 32.7 
P
R
O
T
 
A
s
s
a
y
 I
 
1
5
.6
.0
9
 15 28  53 47 53 59 
17 30  21 41 68 60 
17 28  26 19 53 74 
A
s
s
a
y
 
II
 
1
6
.6
.0
9
 18 20  30 31 37 67 
13 28  29 35 45 69 
15 26  23 25 38 72 
mean 16 27  30 33 49 67 
sd 1.8 3.5  11.6 10.3 11.6 6.2 
 mean sd 
Pos 1135/920/1143/1111/1238/1199 1124 110.4 
Neg 36/33/35/34/30/38/47/40/43/31/32/37 36 5.1 
2xneg 72/66/70/68/60/76/94/80/86/62/64/74 73 10.1 
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9.2. Antimutagenicity tests with TA 102 
 
9.2.1. Single revertant numbers: TA 102 + TNFone 0.2*10-7 µmol7plate 
 
Table 14 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
1
3
.4
.0
9
   453 467 598 607 602 
  425 440 561 583 575 
  416 459 501 487 443 
A
s
s
a
y
 I
I 
2
7
.4
.0
9
   425 500 718 760 681 
  382 564 615 738 521 
  314 526 459 632 622 
mean 403 493 575 635 574 403 493 
 sd 49.0 46.5 91.3 101.6 83.1 49.0 46.5 
B
V
 A
s
s
a
y
 I
 
1
3
.4
.0
9
 490 519   622 496 641 696 
497 517   629 679 708 731 
391 458   565 688 779 556 
A
s
s
a
y
 
II
 
2
7
.4
.0
9
 552 728   674 814 847 824 
623 762   833 799 879 857 
595 920   870 862 880 666 
mean 525 651  699 723 789 722 
 sd 83.9 180.7  123.8 132.7 98.3 109.6 
B
R
-D
T
 
A
s
s
a
y
 I
 
1
3
.4
.0
9
 476 387   519 523 360 519 
489 464   390 513 426 522 
465 406   439 440 517 575 
A
s
s
a
y
 
II
 
2
7
.4
.0
9
 507 537   629 556 594 718 
486 625   631 655 563 697 
533 645   504 702 548 685 
mean 493 511  519 565 501 619 
sd 24.2 109.8  97.9 97.0 90.0 91.2 
P
R
O
T
 
A
s
s
a
y
 I
 
1
3
.4
.0
9
 240 246   298 331 242 355 
302 253   335 336 326 402 
288 272   288 314 407 336 
A
s
s
a
y
 
II
 
2
7
.4
.0
9
 182 237   262 384 397 572 
196 234   240 397 363 463 
189 352   221 420 267 316 
mean 233 266  274 364 334 407 
sd 52.4 44.4  41.5 42.4 68.1 96.3 
 mean sd 
Pos 983/968/972/1124/1429 1095 197.6 
Neg 353/269/278/348/298/316/367/262/381 319 44.8 
2xneg  706/538/556/696/596/632/734/524/762 638 89.5 
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9.2.2. Single revertant numbers: TA 102 + AFB₁ 0.24*10-6 µmol/plate  
 
Table 15 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
1
5
.6
.0
9
   627 603 488 463 825 
  612 645 573 511 762 
  660 679 657 445 496 
A
s
s
a
y
 I
I 
1
5
.6
.0
9
   615 679 739 533 698 
  612 691 748 753 734 
  527 496 623 747 849 
mean   609 632 638 575 727 
 sd   44.1 74.0 99.6 139.0 126.5 
B
V
 A
s
s
a
y
 I
 
1
5
.6
.0
9
 595 526  714 568 866 691 
506 528  751 757 714 735 
591 449  503 647 649 503 
A
s
s
a
y
 
II
 
1
5
.6
.0
9
 482 604  631 659 711 620 
492 591  717 709 732 584 
530 652  724 617 682 609 
mean 533 558  673 660 726 624 
 sd 49.5 71.9  92.7 66.8 74.7 81.6 
B
R
-D
T
 
A
s
s
a
y
 I
 
1
5
.6
.0
9
 457 641  591 510 417 353 
505 668  586 438 534 491 
391 601  432 503 522 650 
A
s
s
a
y
 
II
 
1
5
.6
.0
9
 488 615  644 705 714 602 
536 677  647 727 773 806 
498 423  689 703 726 627 
mean 479 604  598 598 614 588 
sd 50.2 93.5  90.1 127.7 142.5 153.4 
P
R
O
T
 
A
s
s
a
y
 I
 
1
5
.6
.0
9
 306 291  365 457 424 409 
331 273  322 453 445 432 
293 229  357 464 462 428 
A
s
s
a
y
 
II
 
1
5
.6
.0
9
 393 533  563 442 515 513 
457 416  568 470 558 644 
452 472  445 392 382 543 
mean 372 369  437 446 464 495 
sd 72.6 122.2  107.6 28.3 63.4 90.2 
 mean sd 
Pos 1456/1413/1553/1122/1142/1235 1320 178.6 
Neg 
397/364/342/387/377/382/327/313/369/324/
297/251 
344 43.4 
2xneg 
794/728/684/774/754/764/654/626/738/648/
594/502 
688 86.8 
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9.2.3. Single revertant numbers: TA 102 + t-BOOH 0.75*10-6 µmol/plate 
 
Table 16 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
1
0
.5
.0
9
   1979 2005 2171 1738 2294 
  1648 1717 1883 1960 2419 
  2276 1738 2806 1766 2348 
A
s
s
a
y
 I
I 
1
1
.5
.0
9
   2081 2280 2249 1902 2358 
  1719 1831 2063 2299 1820 
  1793 2031 2069 2035 1660 
mean   1916 1934 2207 1950 2150 
 sd   239.4 214.6 318.3 205.1 323.9 
B
V
 A
s
s
a
y
 I
 
1
0
.5
.0
9
 1486 1333  1191 2282 1913 2033 
1426 1502  1531 2682 2292 1720 
1583 1218  920 1767 1983 1330 
A
s
s
a
y
 
II
 
1
1
.5
.0
9
 1194 1656  1810 1730 1929 1947 
1538 1662  1774 1343 2119 1998 
1567 1420  1640 1555 2104 2115 
mean 1466 1465  1478 1893 2057 1857 
 sd 145.0 177.3  352.3 496.6 144.1 290.5 
B
R
-D
T
 
A
s
s
a
y
 I
 
1
0
.5
.0
9
 1605 1597  1671 1550 1490 1949 
1487 1554  1392 1784 1639 1900 
1275 1581  1236 1923 1660 1898 
A
s
s
a
y
 
II
 
1
1
.5
.0
9
 1301 1785  1647 1555 1925 2841 
1340   1849 1845 2245 2757 
1437 1506  1881 1892 2555 2613 
mean 1408 1605  1613 1758 1919 2326 
sd 126.2 106.6  254.2 166.1 410.0 456.1 
P
R
O
T
 
A
s
s
a
y
 I
 
1
0
.5
.0
9
 937 1281  1441 1760 1550 1914 
840 957  1360 1618 1591 1885 
594 1186  1595 1548 1902 1870 
A
s
s
a
y
 
II
 
1
1
.5
.0
9
 994 1187  1468 1765 1986 1900 
975 1445  2130 1685 1990 1989 
773 1723  1762 1799 2003 2000 
mean 852 1297  1626 1696 1837 1926 
sd 152.0 262.2  284.0 97.5 209.9 54.9 
 mean sd 
Pos 2113/2536/2641/2624/2329/ 2449 224.9 
Neg 
318/346/256/395/420/413/406/432/398/374/
375/396 
377 49.8 
2xneg 
636/692/512/790/840/826/812/864/796/748/
750/792 
755 99.5 
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9.2.4. Single revertant numbers: TA 102 + t-BOOH 0.75*10-6 µmol/plate +S9 
 
Table 17 
Sample 
Concentration (µmol/plate) 
2.0 1.0 0.75 0.5 0.1 0.05 0.01 
B
R
 A
s
s
a
y
 I
 
3
0
.6
.0
9
    1278 1338 849 1228 
  1024 1325 1430 868 1233 
  1199 1444 1102 921 1275 
A
s
s
a
y
 I
I 
5
.8
.0
9
   647 1028 645 879 1194 
  917 935 777 1026 1257 
  1030 1135 547 1199 1030 
mean   963 1191 973 957 1203 
 sd   123.7 85.6 169.2 37.3 25.8 
B
V
 A
s
s
a
y
 I
 
3
0
.6
.0
9
 1093 891  1143 820 982 1121 
1114 903  1080 680 888 1017 
987 779  1190 578 946 640 
A
s
s
a
y
 
II
 
5
.8
.0
9
 1604 1129  1265 713 903 1045 
1366 1258  1138 818 1141 1200 
1609 901  1221 1154 524 1107 
mean 1296 977  1173 794 897 1022 
 sd 68.1 68.4  55.2 121.5 47.4 253.1 
B
R
-D
T
 
A
s
s
a
y
 I
 
3
0
.6
.0
9
 1150 904  973 841 1171 1024 
1140 932  917 687 1190 759 
938 1057  963 887 1103 773 
A
s
s
a
y
 
II
 
5
.8
.0
9
 1215 1556  1572 999 1174 1456 
1335 1247  1657 1028 974 1446 
1317 1439  1589 1007 1083 1432 
mean 1183 1189  1279 908 1116 1148 
sd 119.6 81.5  29.9 104.7 45.7 149.1 
P
R
O
T
 
A
s
s
a
y
 I
 
3
0
.6
.0
9
 1366 1946  1520 1382 1437 887 
1196 1763  1636 1632 1648 761 
1361 1895  1541 1462 1534 893 
A
s
s
a
y
 
II
 
5
.8
.0
9
 1421 1282  1488 984 996 754 
1470 1684  1055 1013 1392 1123 
1528 1474  1363 1111 1120 1097 
mean 1390 1674  1434 1264 1355 919 
sd 96.7 94.4  61.8 127.7 105.6 74.5 
 mean sd 
Pos 1274/1056/953/1593/1372/1494/ 1290 163.9 
Neg 
364/413/329/329/326/300/235/258/237/293/
260/253 
300 39.7 
2xneg 
728/826/658/658/652/600/470/516/474/586/
520/506 
600 79.4 
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9.3. Mutagenicity tests with TA 98 
 
9.3.1. Single revertant numbers: TA 98 + TNFone 0.3*10-6 µmol/plate 
 
Table 18 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
0
.8
.0
9
   27  31   
  39  35   
  42  37   
A
s
s
a
y
 I
I 
1
1
.8
.0
9
   37  30   
  46  42   
  36  42   
mean   38  36   
 sd   6.4  5.2   
B
V
 A
s
s
a
y
 I
 
1
0
.8
.0
9
 36    38   
35    41   
42    40   
A
s
s
a
y
 
II
 
1
1
.8
.0
9
 31    44   
25    39   
57    32   
mean 38    39   
 sd 11.0    4.0   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
0
.8
.0
9
 42    37   
42    28   
52    31   
A
s
s
a
y
 
II
 
1
1
.8
.0
9
 39    36   
25    37   
37    39   
mean 40    35   
sd 8.8    4.2   
P
R
O
T
 
A
s
s
a
y
 I
 
1
0
.8
.0
9
 33    36 38 30 
37    41 38 43 
35    35 32 38 
A
s
s
a
y
 
II
 
1
1
.8
.0
9
 38    33 40 37 
32    38 42 37 
39    33 42 40 
mean 36    36 39 38 
sd 2.8    3.1 3.7 4.3 
 mean sd 
Pos 392/404/403/426/398/449 412 21.5 
Neg 31/50/36/31/48/33/22/28/42/34/38/51 37 9.1 
2xneg 62/100/72/62/96/66/44/56/84/68/76/102 74 18.3 
 
 
85 
 
9.3.2. Single revertant numbers: TA 98 + AFB₁ 0.8*10-7 µmol/plate +S9 
 
Table 19 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
2
.8
.0
9
   31  26   
  36  38   
  32  45   
A
s
s
a
y
 I
I 
1
9
.8
.0
9
   48  32   
  36  53   
  37  42   
mean   37  39   
 sd   6.1  9.6   
B
V
 A
s
s
a
y
 I
 
1
2
.8
.0
9
 33    39   
31    33   
30    22   
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 39    46   
27    34   
20    42   
mean 30    36   
 sd 6.3    8.4   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
2
.8
.0
9
 48    42   
48    44   
47    59   
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 46    42   
47    51   
45    47   
mean 47    48   
sd 1.2    6.6   
P
R
O
T
 
A
s
s
a
y
 I
 
1
2
.8
.0
9
 43    46 30 48 
41    52 41 45 
47    48 38 47 
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 39    38 48 48 
34    43 49 46 
42    56 49 44 
mean 41    47 43 46 
sd 4.3    6.4 7.7 1.6 
 mean sd 
Pos 1056/1253/1251/1173/1259/1155 1191 79.9 
Neg 39/37/49/48/46/48/39/27/25/30/49/42 40 8.7 
2xneg 74/74/98/96/92/96/78/54/50/60/98/84 80 17.4 
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9.3.3. Single revertant numbers: TA 98 + PhIP 0.1*10-7 µmol/plate +S9 
 
Table 20 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
2
.8
.0
9
   31  26   
  36  38   
  32  45   
A
s
s
a
y
 I
I 
1
9
.8
.0
9
   48  32   
  36  53   
  37  42   
mean   37  39   
 sd   6.1  9.6   
B
V
 A
s
s
a
y
 I
 
1
2
.8
.0
9
 33    39   
31    33   
30    22   
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 39    46   
27    34   
20    42   
mean 30    36   
 sd 6.3    8.4   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
2
.8
.0
9
 48    42   
48    44   
47    59   
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 46    42   
47    51   
45    47   
mean 47    48   
sd 1.2    6.6   
P
R
O
T
 
A
s
s
a
y
 I
 
1
2
.8
.0
9
 43    46 30 48 
41    52 41 45 
47    48 38 47 
A
s
s
a
y
 
II
 
1
9
.8
.0
9
 39    38 48 48 
34    43 49 46 
42    56 49 44 
mean 41    47 43 46 
sd 4.3    6.4 7.7 1.6 
 mean sd 
Pos 1117/1271/1255/1314/1274/1287 1253 69.5 
Neg 39/37/49/48/46/48/39/27/25/30/49/42 40 8.7 
2xneg 78/74/98/96/92/96/78/54/50/60/98/84 80 17.4 
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9.4. Mutagenicity tests with TA 102 
 
9.4.1. Single revertant numbers: TA 102 + TNFone 0.2*10-7 µmol/plate 
 
Table 21 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
7
.8
.0
9
   312  584   
  202  598   
  403  600   
A
s
s
a
y
 I
I 
1
8
.8
.0
9
   408  456   
  338  364   
  289  214   
mean   325  469   
 sd   77.1  157.0   
B
V
 A
s
s
a
y
 I
 
1
7
.8
.0
9
 494    579   
487    512   
361    364   
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 460    536   
482    537   
493    552   
mean 463    513   
 sd 51.4    76.4   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
7
.8
.0
9
 401    377   
418    461   
445    518   
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 472    446   
519    407   
420    430   
mean 446    440   
sd 43.6    48.4   
P
R
O
T
 
A
s
s
a
y
 I
 
1
7
.8
.0
9
 543    447 533 347 
452    376 517 472 
427    553 484 469 
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 456    527 572 586 
498    444 516 517 
453    435 555 458 
mean 472    464 530 475 
sd 41.9    65.1 31.2 78.5 
 mean sd 
Pos 1217/1185/1245/1233/1307/1259 1241 41.2 
Neg 
460/473/450/422/417/389/333/399/400/407/
456/447/ 
421 39.2 
2xneg 
920/946/900/844/834/778/666/798/800/814/
912/894 
842 78.3 
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9.4.2. Single revertant numbers: TA 102 + AFB₁ 0.24*10-6 µmol/plate +S9 
 
Table 22 
 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
9
.8
.0
9
   257  401   
  280  472   
  275  421   
A
s
s
a
y
 I
I 
2
0
.8
.0
9
   201  322   
  234  394   
  244  399   
mean   249  402   
 sd   29.2  48.4   
B
V
 A
s
s
a
y
 I
 
1
9
.8
.0
9
 361    486   
341    499   
316    383   
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 433    303   
373    318   
335    253   
mean 360    374   
 sd 41.0    101.1   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
9
.8
.0
9
 463    362   
498    481   
522    414   
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 552    417   
566    397   
546    426   
mean 525    416   
sd 38.6    39.0   
P
R
O
T
 
A
s
s
a
y
 I
 
1
9
.8
.0
9
 343    372 424 448 
358    417 376 397 
366    403 373 483 
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 375    395 414 342 
469    400 363 347 
328    399 435 404 
mean 373    398 398 404 
sd 49.8    14.7 30.4 55.3 
 mean sd 
Pos 1768/1413/1315/1118/1475/1358 1408 214.2 
Neg 
367/419/421/374/463/429/352/397/356/397/
387/335/ 
391 37.1 
2xneg 
734/838/842/748/926/858/704/ 
794/712/794/774/670 
783 74.2 
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9.4.3. Single revertant numbers: TA 102 + t-BOOH 0.75*10-6 µmol/plate 
 
Table 23 
 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
7
.8
.0
9
   312  584   
  202  598   
  403  600   
A
s
s
a
y
 I
I 
1
8
.8
.0
9
   408  456   
  338  364   
  289  214   
mean   325  469   
 sd   77.1  157.0   
B
V
 A
s
s
a
y
 I
 
1
7
.8
.0
9
 494    579   
487    512   
361    364   
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 460    536   
482    537   
493    552   
mean 463    513   
 sd 51.4    76.4   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
7
.8
.0
9
 401    377   
418    461   
445    518   
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 472    446   
519    407   
420    430   
mean 446    440   
sd 43.6    48.4   
P
R
O
T
 
A
s
s
a
y
 I
 
1
7
.8
.0
9
 543    447 533 347 
452    376 517 472 
427    553 484 469 
A
s
s
a
y
 
II
 
1
8
.8
.0
9
 456    527 572 586 
498    444 516 517 
453    435 555 458 
mean 472    464 530 475 
sd 41.9    65.1 31.2 78.5 
 mean sd 
Pos 1184/1564/1566/1362/1566/1597 1473 165.4 
Neg 
460/473/450/422/417/389/333/399/400/407/
456/447 
421 39.2 
2xneg 
920/946/900/844/834/778/666/798/800/814/
912/894 
842 78.3 
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9.4.4. Single revertant numbers: TA 102 + t-BOOH 0.75*10-6 µmol/plate +S9 
 
Table 24 
 
 
Sample 
Concentration (µmol/plate) 
2.0  0.75  0.01 0.005 0.001 
B
R
 A
s
s
a
y
 I
 
1
9
.8
.0
9
   257  401   
  280  472   
  275  421   
A
s
s
a
y
 I
I 
2
0
.8
.0
9
   201  322   
  234  394   
  244  399   
mean   249  402   
 sd   29.2  48.4   
B
V
 A
s
s
a
y
 I
 
1
9
.8
.0
9
 361    486   
341    499   
316    383   
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 433    303   
373    318   
335    253   
mean 360    374   
 sd 41.0    101.1   
B
R
-D
T
 
A
s
s
a
y
 I
 
1
9
.8
.0
9
 463    362   
498    481   
522    414   
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 552    417   
566    397   
546    426   
mean 525    416   
sd 38.6    39.0   
P
R
O
T
 
A
s
s
a
y
 I
 
1
9
.8
.0
9
 343    372 424 448 
358    417 376 397 
366    403 373 483 
A
s
s
a
y
 
II
 
2
0
.8
.0
9
 375    395 414 342 
469    400 363 347 
328    399 435 404 
mean 373    398 398 404 
sd 49.8    14.7 30.4 55.3 
 mean sd 
Pos 1452/1649/1410/1508/1548 1513 92.3 
Neg 
367/419/421/374/463/429/352/397/356/397/
387/335/ 
391 37.1 
2xneg 
734/838/842/748/926/858/704/ 
794/712/794/774/670 
783 74.2 
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